<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Endocrine System - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  background: url("assets/background.jpg") center center / cover no-repeat fixed;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
}

body::before {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* Responsive utilities */
@media (max-width: 768px) {
  .glass-card {
    border-radius: 16px;
  }
  
  .glass {
    border-radius: 12px;
  }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">74</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="flex container mx-auto px-6 gap-8">
        <!-- Question Navigation Sidebar -->
        <div class="w-80 glass p-6 h-fit sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="flex-1 max-w-4xl">
            <div class="glass-card p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <!-- Explanation Video -->
                    <div id="solutionVideo" class="hidden">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

    <script>
        let questionsData = [
  {
    "id": 3733,
    "choices": [
      {
        "id": 14911,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is effective orally.</span></span></span></p>"
      },
      {
        "id": 14912,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used for the treatment of acromegaly.</span></span></span></p>"
      },
      {
        "id": 14913,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be used for the management of secretory Diarrhea.</span></span></span></p>"
      },
      {
        "id": 14914,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be used in portal hypertension.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements about octreotide are true except.</span></span></span></p>",
    "unique_key": "Q6616879",
    "question_audio": null,
    "question_video": null,
    "map_id": 36090,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. It is effective orally.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is effective orally</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is<strong> not true</strong> about<strong> octreotide</strong>. <strong>Octreotide is a synthetic analogue of somatostatin </strong>and its therapeutic effects are primarily through <strong>parenteral route</strong>s, such as <strong>subcutaneous or intravenous injections</strong>. The<strong> oral bioavailability of octreotide is</strong> <strong>extremely low</strong> due to its<strong> rapid degradation</strong> in the g<strong>astrointestinal tract</strong> and its <strong>inability to be effectively absorbed </strong>when taken by <strong>mouth</strong>. Therefore, it is<strong> not used or effective in oral form for clinical purposes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <em>Drugs ending with <strong>&lsquo;tide&rsquo; are peptides</strong> and are <strong>not effective orally </strong></em></span><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>because</strong>, the <strong>presence of peptidases (like pepsin, trypsin </strong>etc.) in the GIT&nbsp; will <strong>make these inactive.</strong></span></em></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. It is used for the treatment of acromegaly</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This statement is <strong>true</strong>. <strong>Octreotide</strong> is used in the<strong> treatment of acromegaly,</strong> a condition characterized by<strong> excessive growth hormone production, leading to enlarged</strong> features. <strong>Octreotide </strong>helps by <strong>inhibiting</strong> <strong>growth hormone secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. It can be used for the management of secretory Diarrhea</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is also<strong> true.</strong> Octreotide can manage <strong>secretory diarrhea,</strong> including that<strong> caused by certain tumors (like carcinoid tumors or VIPomas),</strong> by <strong>inhibiting the secretion</strong> of various gastrointestinal <strong>hormones and substances.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. It can be used in portal hypertension</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>True.</strong> Octreotide is used in the management of <strong>portal hypertension, </strong>particularly to <strong>control variceal bleeding, </strong>by <strong>reducing blood flow</strong> to the<strong> gastrointestinal tract</strong> and<strong> lowering portal vein pressure.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While<strong> octreotide</strong> is a valuable medication in the management of <strong>acromegaly, secretory diarrhea, and portal hypertension,</strong> it must be administered through<strong> parenteral routes</strong> due to its<strong> poor oral bioavailability. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> - You can remember this fact from the name of the drug. If the <strong>name of a drug ends with &lsquo;tide&rsquo;,</strong> it is a <strong>peptide and peptides</strong> <strong>cannot be given orally</strong> because, the <strong>presence of peptidases (like pepsin, trypsin etc.)</strong> will make these <strong>inactive.</strong></span></span></span></p>",
    "correct_choice_id": 14911,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 3725,
    "choices": [
      {
        "id": 14879,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sumatriptan</span></span></span></p>"
      },
      {
        "id": 14880,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bromocriptine</span></span></span></p>"
      },
      {
        "id": 14881,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ergotamine</span></span></span></p>"
      },
      {
        "id": 14882,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Allopurinol</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 22-year-old female, Neeta, presented to you with complaints of headache and vomiting for 2 months. She has amenorrhea, but the urine pregnancy test is negative. She also complained of secretion of milk from the breasts. A provisional diagnosis of hyperprolactinemia was made, and MRI was suggested. MRI confirmed the presence of a large pituitary adenoma. Neeta was advised surgery; however, she is not willing to undergo surgery. Which of the following medications is most likely to be prescribed to control her symptoms?</span></span></span></p>",
    "unique_key": "Q1682011",
    "question_audio": null,
    "question_video": null,
    "map_id": 36085,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Bromocriptine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bromocriptine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a<strong> dopamine agonist</strong> that is effective in the treatment of <strong>hyperprolactinemia, </strong>which is characterized by <strong>elevated</strong> <strong>levels of prolactin </strong>leading to symptoms such as<strong> amenorrhea, galactorrhea (secretion of milk from the breasts), headache, </strong>and in some cases,<strong> vision problems </strong>due to <strong>pituitary adenomas</strong>. Bromocriptine works by <strong>binding to dopamine D2 receptors </strong>in the pituitary gland, which<strong> inhibits the secretion of prolactin</strong>. In addition to <strong>lowering prolactin levels</strong>, bromocriptine can also <strong>reduce the size of</strong> <strong>prolactin-secreting pituitary adenomas</strong>, thus <strong>helping to alleviate </strong>symptoms associated with the<strong> tumor</strong>, including <strong>headaches and</strong> <strong>vision issues.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Sumatriptan</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Sumatriptan is a medication<strong> used to treat acute migraine headaches</strong>. It is a <strong>serotonin receptor agonist</strong> that causes<strong> vasoconstriction of cranial blood vessels.</strong> It is<strong> not </strong>used in the treatment of<strong> hyperprolactinemia or pituitary adenomas.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ergotamine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Ergotamine is<strong> used for </strong>the treatment of <strong>migraine headaches</strong>. It is an <strong>ergot alkaloid </strong>that causes <strong>vasoconstriction. </strong>It<strong> does not</strong> reduce<strong> prolactin levels or treat pituitary adenomas.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Allopurinol</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Allopurinol is used to <strong>decrease high blood uric acid levels</strong>, as seen in <strong>gout </strong>and certain types of <strong>kidney stones. </strong>It is not relevant to the treatment of hyperprolactinemia or pituitary adenomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bromocriptine</strong> is the appropriate pharmacological treatment for<strong> hyperprolactinemia </strong>caused by a<strong> pituitary adenoma</strong>, especially when surgery is not an option. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bromocriptine</strong> is the preferred<strong> choice</strong> due to its dual role in<strong> reducing prolactin levels and potentially decreasing the size of the</strong> <strong>adenoma</strong>, thus addressing<strong> both </strong>the <strong>hormonal imbalance and its physical cause.</strong> </span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> </span></span></span></p>",
    "correct_choice_id": 14880,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 3729,
    "choices": [
      {
        "id": 14895,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glucagonoma</span></span></span></p>"
      },
      {
        "id": 14896,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulinoma</span></span></span></p>"
      },
      {
        "id": 14897,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carcinoid syndrome</span></span></span></p>"
      },
      {
        "id": 14898,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glioma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Octreotide is used in all except? </span></span></span></p>",
    "unique_key": "Q5738935",
    "question_audio": null,
    "question_video": null,
    "map_id": 36087,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Glioma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glioma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> refers to a type of<strong> tumor</strong> that arises from<strong> glial cells</strong> in <strong>the brain or spinal cord. Octreotide,</strong> a<strong> somatostatin analogue, </strong>is <strong>not</strong> used in the treatment of <strong>gliomas. Octreotide&#39;</strong>s mechanism of action involves <strong>mimicking natural somatostatin</strong> to<strong> inhibit the secretion</strong> of several hormones, including <strong>growth hormone, glucagon, and insulin, </strong>making it useful in conditions related to<strong> excessive</strong> <strong>hormone secretion,</strong> but i<strong>t does not </strong>have a therapeutic role in the treatment of <strong>gliomas,</strong> which are <strong>primary brain or spinal cord</strong> <strong>tumors</strong>. The <strong>drug of choice</strong> for <strong>glioma is temozolomide.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Glucagonoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Octreotide</strong> is used in the management of <strong>glucagonoma,</strong> a rare type of <strong>pancreatic neuroendocrine tumor</strong> that <strong>secretes excessive amounts of glucagon. </strong>Octreotide helps in controlling symptoms by <strong>inhibiting glucagon secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Insulinoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Although <strong>insulinomas produce excessive insulin,</strong> <strong>octreotide</strong> can sometimes be used in the management of these tumors to<strong> help control hypoglycemia</strong>, particularly in patients with <strong>metastatic disease </strong>or those who are <strong>not candidates for</strong> <strong>surgery.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Carcinoid syndrome</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Octreotide </strong>is effectively used in the treatment of<strong> carcinoid syndrome</strong>, which is characterized by <strong>flushing, diarrhea, and wheezing </strong>due to the<strong> secretion of serotonin </strong>and other<strong> vasoactive substances</strong> by <strong>carcinoid tumors.</strong> <strong>Octreotide</strong> helps in reducing these symptoms by <strong>inhibiting the secretion of these substances.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uses of Octreotide</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture8.jpg\" style=\"height:228px; width:1000px\" /></p>",
    "correct_choice_id": 14898,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3693,
    "choices": [
      {
        "id": 14751,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anterior thigh</span></span></span></p>"
      },
      {
        "id": 14752,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lateral thigh</span></span></span></p>"
      },
      {
        "id": 14753,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Upper arm</span></span></p>"
      },
      {
        "id": 14754,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Around umbilicus</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following sites is least commonly preferred for insulin injection? </span></span></span></p>",
    "unique_key": "Q8388063",
    "question_audio": null,
    "question_video": null,
    "map_id": 36084,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D. Around umbilicus</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sites of Insulin Injection</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Insulin </strong>usually is <strong>injected</strong> into the <strong>subcutaneous tissues of the abdomen, buttock, anterior and lateral thigh or upper arm.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Absorption </strong>is variable in the area<strong> around the umbilicus, </strong>therefore this site is not recommended for insulin administration.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Absorption</strong> is usually <strong>most rapid from the abdominal wall,</strong> followed by the<strong> arm, buttock, and thigh.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">If a patient is willing to<strong> inject into the abdomen, injections</strong> can be <strong>rotated throughout the entire area, </strong>thereby <strong>eliminating the injection site </strong>as a cause of variability in the <strong>rate of absorption.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The <strong>abdomen currently</strong> is the preferred <strong>site of injection</strong> because<strong> insulin is absorbed 20&ndash;30% faster from that site</strong> than <strong>from the arm.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Rotation of insulin injection</strong> sites traditionally has been advocated to <strong>avoid lipohypertrophy or lipoatrophy, </strong>although these conditions are i<strong>nfrequent with current preparations of insulin.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Option A. Anterior thigh </strong>and<strong> B. Lateral thigh C. Upper arm:</strong> These areas are <strong>common for insulin injections</strong> and provide <strong>consistent</strong> <strong>absorption</strong>, although generally <strong>slower </strong>compared to the <strong>abdominal wall.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SITES OF INSULIN INJECTION</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture5.jpg\" style=\"height:385px; width:600px\" /></p>",
    "correct_choice_id": 14754,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3658,
    "choices": [
      {
        "id": 14611,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypotensive state</span></span></span></p>"
      },
      {
        "id": 14612,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alcoholics</span></span></span></p>"
      },
      {
        "id": 14613,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal failure</span></span></span></p>"
      },
      {
        "id": 14614,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypokalemia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following are contraindications for the use of metformin except?</span></span></span></p>",
    "unique_key": "Q4570542",
    "question_audio": null,
    "question_video": null,
    "map_id": 36082,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Hypokalemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metformin is a biguanide </strong>class of antidiabetic medication primarily used for the management of<strong> Type 2 diabetes mellitus</strong>. It works by <strong>decreasing hepatic glucose production </strong>and <strong>improving insulin sensitivity. </strong>It can <strong>increase risk of lactic acidosis </strong>particularly in patients with<strong> liver disease, renal disease </strong>and those<strong> pre-disposed to hypoxia</strong>. While it has <strong>several contraindications, hypokalemia (low potassium levels) is not </strong>directly related to its<strong> use or its mechanism of action</strong>. Therefore, the presence of <strong>hypokalemia does not preclude the use of metformin</strong>, provided that the<strong> hypokalemia itself is managed appropriately.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hypotensive state</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While <strong>not a direct contraindication, </strong>caution is advised in conditions that may <strong>predispose patients to hypotension</strong>, as <strong>low perfusion </strong>may<strong> increase the risk of metformin </strong>induced <strong>lactic acidosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Alcoholics</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Chronic and excessive alcohol </strong>consumption is a <strong>contraindication for metformin </strong>use due to the<strong> increased risk of lactic acidosis</strong>, especially in cases of<strong> hepatic impairment and acute alcohol intoxication.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Renal failure</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Renal failure or significant <strong>renal impairment is a contraindication </strong>for the use of<strong> metformin </strong>due to the <strong>increased risk of accumulating metformin </strong>and subsequent<strong> lactic acidosis</strong>. Latest guidelines regarding use of<strong> metformin in renal dysfunction </strong>include:</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture1.jpg\" style=\"height:229px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Risk factors for metformin induced lactic acidosis</span></em></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatic failure </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal failure </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alcoholics</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metabolic acidosis</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elderly</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Conditions predisposing to hypoxia (Shock, CHF, Severe anemia, Major surgery etc.)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mnemonic:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">MET: MET</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">abolic</span><strong> </strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">acidosis</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">F: F</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ailure (Liver and Renal failure)</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">O R MIN: O</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">xygen&nbsp;</span><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">R</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">eaching the tissues is&nbsp;</span><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">MIN</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">imum (means hypoxia causing conditions)</span></span></span></p>",
    "correct_choice_id": 14614,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3957,
    "choices": [
      {
        "id": 15807,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raloxifene</span></span></span></p>"
      },
      {
        "id": 15808,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bisphosphonates</span></span></span></p>"
      },
      {
        "id": 15809,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teriparatide</span></span></span></p>"
      },
      {
        "id": 15810,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given figure shows the mechanism of action of Drug Y in treatment of osteoporosis. Which of the following best represents drug Y?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture16.jpg\" style=\"height:381px; width:600px\" /></p>",
    "unique_key": "Q9213385",
    "question_audio": null,
    "question_video": null,
    "map_id": 36089,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Denosumab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The figure illustrates that <strong>Drug Y inhibits the binding of RANKL to RANK, </strong>which is crucial for the <strong>formation, function, and survival of</strong> <strong>osteoclasts. Denosumab is a monoclonal antibody </strong>designed to <strong>target RANKL</strong>, thereby preventing it from <strong>activating RANK on</strong> <strong>osteoclasts and their precursors</strong>. This<strong> inhibition</strong> effectively reduces the<strong> formation and activity of osteoclasts,</strong> leading to a<strong> decrease in bone resorption.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Raloxifene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect&nbsp;</strong>for this mechanism.<strong> Raloxifene is a selective estrogen receptor modulator (SERM) </strong>that mimics <strong>estrogen&#39;s bone-protective effect</strong>s by <strong>reducing osteoclast activity,</strong> but it<strong> does not</strong> work by targeting the<strong> RANKL-RANK interaction.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Bisphosphonates:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Also<strong> incorrect. </strong>Bisphosphonates<strong> inhibit</strong> <strong>osteoclast-mediated bone resorption</strong> by inducing <strong>osteoclast</strong> <strong>apoptosis </strong>and interfering with the<strong> mevalonate pathway</strong>, not by RANKL inhibition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Teriparatide:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect&nbsp;</strong>for this illustration. <strong>Teriparatide,</strong> a recombinant form of <strong>parathyroid hormone</strong>, primarily works by <strong>stimulating osteoblasts</strong> to promote <strong>bone formation rather than inhibiting osteoclasts.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Denosumab</strong> is used in the treatment of <strong>osteoporosis by targeting the RANKL-RANK interaction</strong>, effectively <strong>inhibiting osteoclast</strong> formation and activity, thus <strong>decreasing bone resorption.</strong></span></span></span></p>",
    "correct_choice_id": 15810,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 3668,
    "choices": [
      {
        "id": 14651,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It belongs to sulfonylurea class of drugs.</span></span></span></p>"
      },
      {
        "id": 14652,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is not well absorbed on oral administration.</span></span></span></p>"
      },
      {
        "id": 14653,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used to control sleep time hyperglycemia.</span></span></span></p>"
      },
      {
        "id": 14654,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It should be avoided in patients with liver disease.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old patient with Type 2 diabetes mellitus is being evaluated for potential adjustments to their glucose-lowering therapy. The patient&#39;s current regimen includes metformin and a once-daily basal insulin. Despite these treatments, the patient&#39;s glycemic control remains suboptimal, with particular difficulty managing postprandial blood sugar spikes. The patient has a history of non-alcoholic fatty liver disease but normal liver function tests. The healthcare provider is considering adding repaglinide for treatment of this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is true about repaglinide?</span></span></span></p>",
    "unique_key": "Q4909937",
    "question_audio": null,
    "question_video": null,
    "map_id": 36088,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. It should be avoided in patients with liver disease.&nbsp;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Repaglinide </strong>is a medication that should be used with<strong> caution in patients with liver disease</strong>. It is <strong>metabolized by the liver</strong>, and its use in patients with <strong>impaired liver function </strong>could <strong>lead to an increased risk of hypoglycemia </strong>due to <strong>decreased drug clearance</strong>. Although <strong>not an absolute contraindication,</strong> careful consideration, monitoring, and possibly <strong>dose adjustments </strong>are recommended when prescribing<strong> repaglinide to patients with liver disease</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. It belongs to the sulfonylurea class of drugs.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is <strong>incorrect. Repaglinide </strong>is a<strong> meglitinide</strong>, <strong>not a sulfonylurea</strong>. Both classes of drugs <strong>stimulate insulin secretion from the pancreas </strong>but through slightly different mechanisms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. It is not well absorbed on oral administration.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is <strong>incorrect. Repaglinide </strong>is<strong> well absorbed </strong>when taken <strong>orally</strong>, which is why it is effective in <strong>controlling postprandial (after meal) blood glucose levels</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. It is used to control sleep time hyperglycemia.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is<strong> incorrect. Repaglinide </strong>is primarily used to control <strong>postprandial hyperglycemia</strong>, not sleep time hyperglycemia. It has a <strong>rapid onset and short duration of action</strong>, making it suitable for taking<strong> before meals to manage blood sugar spikes after eating</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Repaglinide </strong>is a <strong>meglitinide </strong>class medication used for the management of<strong> postprandial hyperglycemia </strong>in patients with<strong> Type 2 diabetes</strong>. It is important to understand that while <strong>repaglinide </strong>is effective in <strong>controlling blood glucose levels after meals</strong>, caution is advised when prescribing it to patients with<strong> liver disease </strong>due to potential <strong>alterations in drug metabolism and clearance.</strong></span></span></p>",
    "correct_choice_id": 14654,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3736,
    "choices": [
      {
        "id": 14923,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Contraindicated in hyperthyroidism.</span></span></span></p>"
      },
      {
        "id": 14924,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Causes iodism.</span></span></span></p>"
      },
      {
        "id": 14925,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibits the release of thyroxine.</span></span></span></p>"
      },
      {
        "id": 14926,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibits the synthesis of iodo thyroxine and iodothyronine.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about iodine is false?</span></span></span></p>",
    "unique_key": "Q2268059",
    "question_audio": null,
    "question_video": null,
    "map_id": 36092,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Contraindicated in hyperthyroidism.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The statement <strong>&quot;Contraindicated in hyperthyroidism&quot;</strong> is <strong>false regarding iodine</strong>. Iodine, particularly in the <strong>form of potassium iodide</strong>, can be used in certain<strong> hyperthyroidism</strong> contexts, such as preparing a patient with <strong>hyperthyroidism for thyroidectomy </strong>or treating <strong>thyroid storm.</strong> Iodine can <strong>temporarily inhibit the release of thyroid hormones</strong> through the <strong>Wolff-Chaikoff effect</strong>, making it useful in these scenarios. Thus, it is<strong> not universally contraindicated in hyperthyroidism</strong>; instead, its use is specific and strategic in the management of the condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Causes iodism</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This statement is true. Iodism refers to a set of symptoms including metallic taste, burning mouth and throat, sore teeth and gums, symptoms of a head cold, and sometimes stomach upset and diarrhea. These symptoms can occur with the use of iodine supplements or drugs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Inhibits the release of thyroxine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: True. High doses of iodine can temporarily inhibit the release of thyroxine (T4) and triiodothyronine (T3) from the thyroid gland, a phenomenon known as the Wolff-Chaikoff effect.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Inhibits the synthesis of iodo thyroxine and iodothyronine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: True. Iodine in large doses can inhibit the synthesis of thyroid hormones (thyroxine [T4] and triiodothyronine [T3]) by interfering with the iodination of tyrosyl residues in thyroglobulin and the coupling of iodotyrosyl residues to form iodothyronines.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Iodine is not universally contraindicated in hyperthyroidism. It can be used strategically to manage certain aspects of the condition, such as preoperative preparation and acute crisis management, through its temporary inhibitory effects on thyroid hormone synthesis and release.</span></span></p>",
    "correct_choice_id": 14923,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3741,
    "choices": [
      {
        "id": 14943,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">SGLT 2 inhibitor</span></span></span></p>"
      },
      {
        "id": 14944,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">DPP IV inhibitor</span></span></span></p>"
      },
      {
        "id": 14945,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Meglitinide analogues</span></span></span></p>"
      },
      {
        "id": 14946,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">GLP1 agonist</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following antidiabetic drugs act by release of insulin except?</span></span></span></p>",
    "unique_key": "Q6794318",
    "question_audio": null,
    "question_video": null,
    "map_id": 36093,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. SGLT 2 inhibitor </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SGLT2 inhibitors like canagliflozin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> act by a mechanism that<strong> does not</strong> involve the<strong> release of insulin.</strong> <strong>Sodium-glucose cotransporter 2</strong> <strong>(SGLT2) inhibitors</strong> work by <strong>blocking the SGLT2 protein in the kidneys, </strong>which leads to the<strong> reduction of glucose reabsorption </strong>in the <strong>renal tubules, </strong>thereby<strong> increasing glucose excretion in the urine</strong>. This mechanism<strong> lowers blood glucose levels independently of</strong> <strong>insulin secretion or action, </strong>making it<strong> distinct from</strong> the <strong>other options</strong> listed, which are associated with<strong> insulin release or its effects.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. DPP-IV inhibitor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: DPP-IV inhibitors like <strong>sitagliptin work by inhibiting the enzyme dipeptidyl peptidase-4, </strong>which is responsible for the <strong>degradation of incretin hormones.</strong> By<strong> inhibiting this enzyme, </strong>the <strong>levels of incretin hormones (such as GLP-1) are</strong> <strong>increased, </strong>which in turn <strong>stimulates the release of insulin in a glucose-dependent manner.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Meglitinide analogues</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Meglitinide analogues like<strong> repaglinide stimulate the pancreas to release more insulin</strong>. They<strong> bind</strong> to <strong>specific channels on pancreatic beta cells, </strong>causing these<strong> cells to release insulin,</strong> thereby<strong> reducing blood glucose levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. GLP-1 agonist</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: GLP-1 agonists like <strong>exenatide mimic </strong>the action of the <strong>incretin hormone GLP-1, </strong>which <strong>increases insulin</strong> <strong>secretion</strong> from the pancreas in a<strong> glucose-dependent manner. </strong>Additionally,<strong> GLP-1 agonists reduce glucagon secretion and slow</strong> <strong>gastric emptying.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">CLASSIFICATION OF ANTI-DIABETIC DRUGS </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture9.jpg\" style=\"height:827px; width:1000px\" /></p>",
    "correct_choice_id": 14943,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 4237,
    "choices": [
      {
        "id": 16925,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is the only approved inhalational insulin.</span></span></span></p>"
      },
      {
        "id": 16926,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used before meals to control postprandial hyperglycemia.</span></span></span></p>"
      },
      {
        "id": 16927,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is indicated as a replacement for injectable insulin.</span></span></span></p>"
      },
      {
        "id": 16928,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It should be avoided in chronic smokers.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 43-year-old man with type 2 diabetes mellitus is interested in alternative methods of insulin administration because he has difficulty with injections due to a significant needle phobia. He has heard about an inhaled form of insulin and asks about its use and any potential limitations. Which of the following statements about inhaled insulin (Afrezza) is incorrect? </span></span></span></p>",
    "unique_key": "Q2906803",
    "question_audio": null,
    "question_video": null,
    "map_id": 36086,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Indicated as a replacement for injectable insulin.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Afrezza,</strong> an <strong>inhaled insulin</strong>, is <strong>not </strong>typically indicated as a<strong> complete replacement for injectable insulin</strong>. While <strong>Afrezza </strong>can be used to manage<strong> postprandial hyperglycemia in adults with diabetes</strong> and is taken <strong>before meals, i</strong>t is usually used in <strong>conjunction</strong> with<strong> long-acting insulin </strong>in patients with <strong>type 1 diabetes</strong> and is<strong> not </strong>a <strong>substitute for basal insulin. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. It is the only approved inhalational insulin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is<strong> correct. Afrezza</strong> is currently the only <strong>inhalational insulin</strong> approved by the <strong>FDA.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. It is used before meals to control postprandial hyperglycemia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is <strong>correct</strong>.<strong> Afrezza</strong> is a <strong>rapid-acting insulin</strong> taken at the<strong> beginning of a meal</strong> to <strong>control blood sugar spikes after eating.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. It should be avoided in chronic smokers:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is <strong>correct. Afrezza is contraindicated</strong> in patients who <strong>smoke or</strong> have <strong>recently stopped smoking </strong>because of the <strong>risk </strong>of<strong> acute bronchospasm.</strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective:</u></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Inhaled insulin (Afrezza) </strong>is an innovative <strong>rapid-acting insulin </strong>administered <strong>before meals</strong> to manage <strong>postprandial hyperglycemia, </strong>but it is<strong> not</strong> a <strong>full substitute for injectable insulin,</strong> especially in terms of providing <strong>basal insulin coverage.</strong></span></span></p>",
    "correct_choice_id": 16927,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 4117,
    "choices": [
      {
        "id": 16447,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Age.</span></span></p>"
      },
      {
        "id": 16448,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Erosive esophagitis.</span></span></span></p>"
      },
      {
        "id": 16449,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liver disease.</span></span></span></p>"
      },
      {
        "id": 16450,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyroid disease.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old female has been diagnosed with postmenopausal osteoporosis. She has a past medical history of ethanol abuse, alcoholic liver disease, erosive esophagitis, and hypothyroidism. Which of the following would be the primary reason oral bisphosphonates should be used with caution in this patient?</span></span></span></p>",
    "unique_key": "Q9941177",
    "question_audio": null,
    "question_video": null,
    "map_id": 36091,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Erosive esophagitis</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bisphosphonates </strong>are medications used to <strong>prevent the loss of bone mass. </strong>They can cause <strong>esophageal irritation and exacerbate pre-existing esophagitis.</strong> In patients with<strong> erosive esophagitis, </strong>the <strong>use of oral bisphosphonates</strong> <strong>can worsen their condition</strong>, leading to <strong>increased esophageal damage and discomfort</strong>. Therefore, they should be used with<strong> caution or avoided in such cases.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Age:</strong> While the <strong>incidence of osteoporosis increases with age,</strong> age itself is <strong>not </strong>a reason to use <strong>bisphosphonates with</strong> <strong>caution. </strong>These medications are actually often <strong>indicated</strong> to manage<strong> osteoporosis in older adults.</strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Liver disease:</strong> Liver disease is<strong> not a direct contraindication for the use of bisphosphonates.</strong> These drugs are primarily <strong>cleared by the kidneys</strong>, so <strong>liver impairment does not typically impact their use or dosing.</strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Thyroid disease:</strong> Thyroid disease, <strong>specifically hypothyroidism,</strong> is <strong>not a contraindication for bisphosphonate</strong> therapy. However, <strong>thyroid hormone levels </strong>should be managed appropriately as <strong>thyroid dysfunction can influence bone metabolism.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Oral bisphosphonates </strong>should be<strong> used with caution in patients with a history of erosive esophagitis</strong> due to the <strong>risk of esophageal</strong> <strong>irritation and potential exacerbation of the esophageal condition.</strong></span></span></span></span></span></span></p>",
    "correct_choice_id": 16448,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 4266,
    "choices": [
      {
        "id": 17041,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dexamethasone</span></span></span></p>"
      },
      {
        "id": 17042,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Betamethasone</span></span></span></p>"
      },
      {
        "id": 17043,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triamcinolone</span></span></span></p>"
      },
      {
        "id": 17044,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prednisolone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following steroids have selective action on glucocorticoid receptors except?</span></span></span></p>",
    "unique_key": "Q3112938",
    "question_audio": null,
    "question_video": null,
    "map_id": 36083,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Prednisolone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Prednisolone</strong> exhibits both <strong>glucocorticoid and mineralocorticoid activities</strong>, unlike the other options listed which<strong> primarily exert</strong> effects through <strong>glucocorticoid receptors</strong>. Prednisolone&#39;s ability to act on <strong>both types of receptors means i</strong>t has a broader range of effects, impacting <strong>not only inflammation and immune response</strong>s but also<strong> electrolyte and fluid balance</strong>. This<strong> dual activity </strong>can influence its<strong> side effect profile and clinical use,</strong> particularly in conditions where <strong>mineralocorticoid effects </strong>are either<strong> undesirable or</strong> need to be <strong>carefully managed.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Dexamethasone</strong>, <strong>B.</strong> <strong>Betamethasone</strong>, <strong>and C.</strong> <strong>Triamcinolone</strong> are noted for their <strong>high glucocorticoid activity </strong>with <strong>minimal to</strong> <strong>no mineralocorticoid effects.</strong> These<strong> steroids</strong> are particularly useful when <strong>strong anti-inflammatory action</strong> is needed without the accompanying<strong> salt and water retention</strong> that can accompany <strong>mineralocorticoid activity.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/picture3.jpg\" style=\"height:611px; width:1000px\" /></p>",
    "correct_choice_id": 17044,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3751,
    "choices": [
      {
        "id": 14983,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liraglutide</span></span></span></p>"
      },
      {
        "id": 14984,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
      },
      {
        "id": 14985,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Canagliflozin</span></span></span></p>"
      },
      {
        "id": 14986,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pioglitazone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">An obese diabetic patient was on metformin monotherapy, but his sugar levels were not well controlled. He is allergic to sulfa drugs and does not comply with injectable drugs. He has a history of pancreatitis, and family history of bladder carcinoma. In view of the raised glucose levels, you wish to add another anti-diabetic drug. Which one would you prefer? </span></span></span></p>",
    "unique_key": "Q7413394",
    "question_audio": null,
    "question_video": null,
    "map_id": 36103,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Canagliflozin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In this clinical scenario, the <strong>choice of an additional anti-diabetic drug </strong>must consider the patient&rsquo;s <strong>specific health background </strong>and preferences. <strong>Canagliflozin</strong>, a <strong>sodium-glucose cotransporter 2 (SGLT2) inhibitor,</strong> is the most appropriate option. This class of medication<strong> lowers blood sugar </strong>by causing the <strong>kidneys to remove sugar from the body</strong> through the <strong>urine.</strong> It is suitable because it <strong>does not</strong> involve <strong>injection and does</strong> <strong>not </strong>have a known association with<strong> increased risk of pancreatitis or bladder carcinoma.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Liraglutide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Not </strong>suitable as it is an<strong> injectable GLP-1 receptor agonist,</strong> and the patient has a<strong> non-compliance issue</strong> with injectable medications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Sitagliptin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A <strong>DPP-4 inhibitor,</strong> which has been associated with <strong>cases of pancreatitis</strong>, making it a <strong>less suitable </strong>option for a patient with a history of this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pioglitazone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A <strong>thiazolidinedione</strong> that has been associated with an i<strong>ncreased risk of bladder cancer</strong>, especially in individuals with a<strong> family history of the disease</strong>, thus <strong>contraindicating its use in this patient.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture10.jpg\" style=\"height:415px; width:1000px\" /><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture11.jpg\" style=\"height:519px; width:1000px\" /></p>",
    "correct_choice_id": 14985,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3651,
    "choices": [
      {
        "id": 14583,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">30% Amorphous + 70% Crystalline insulin</span></span></span></p>"
      },
      {
        "id": 14584,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">30% Crystalline + 70% Amorphous insulin</span></span></span></p>"
      },
      {
        "id": 14585,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Same as NPH insulin</span></span></span></p>"
      },
      {
        "id": 14586,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only 70% amorphous insulin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lente insulin is composed of.</span></span></span></p>",
    "unique_key": "Q3278399",
    "question_audio": null,
    "question_video": null,
    "map_id": 36101,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. 30% Amorphous &plusmn;70% Crystalline insulin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Lente insulin</strong>, also known as<strong> Insulin Zinc Suspension</strong>, is a type of <strong>intermediate-acting insulin</strong> used to manage <strong>blood sugar levels</strong> in people with <strong>diabetes. </strong>It is composed of a<strong> mixture of 30% amorphous (or non-crystalline) and 70% crystalline insulin</strong>. This specific composition allows for a <strong>delayed absorption of insulin</strong>, providing a <strong>longer duration of action </strong>compared to short-acting insulin formulations. The <strong>crystalline portion dissolves slowly</strong>, ensuring a<strong> sustained release of insulin </strong>into the bloodstream, which helps in maintaining <strong>blood glucose levels </strong>more <strong>evenly over the day</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">30% Crystalline + 70% Amorphous insulin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This option <strong>inversely describes </strong>the composition of<strong> Lente insulin</strong>. The correct composition for Lente insulin is <strong>30% amorphous and 70% crystalline, </strong>not the other way around.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Same as NPH insulin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>NPH (Neutral Protamine Hagedorn) </strong>insulin is another type of <strong>intermediate-acting insulin</strong>, but its composition <strong>differs from </strong>that of <strong>Lente insulin</strong>. NPH insulin is formulated by<strong> combining insulin with protamine </strong>to <strong>delay its action</strong>, not by varying the proportions of amorphous and crystalline insulin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Only 70% amorphous insulin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This option <strong>does not </strong>accurately describe any <strong>standard insulin formulation. </strong>Lente insulin specifically contains both amorphous and crystalline insulin in the proportions of 30% and 70%, respectively.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Lente insulin&#39;s </strong>unique composition of <strong>30% amorphous and 70% crystalline insulin </strong>ensures a<strong> delayed absorption</strong>, providing an <strong>intermediate duration of action </strong>that is crucial for maintaining <strong>stable blood glucose levels </strong>in <strong>diabetes management</strong>.</span></span></span></p>",
    "correct_choice_id": 14583,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3683,
    "choices": [
      {
        "id": 14711,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Advanced age</span></span></span></p>"
      },
      {
        "id": 14712,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Smoking</span></span></span></p>"
      },
      {
        "id": 14713,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liver dysfunction</span></span></span></p>"
      },
      {
        "id": 14714,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal failure</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin causes a severe, sometimes life-threatening side effect of lactic acidosis. All the following factors increase the risk of lactic acidosis except.</span></span></span></p>",
    "unique_key": "Q1062940",
    "question_audio": null,
    "question_video": null,
    "map_id": 36100,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Smoking </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metformin </strong>is a<strong> biguanide </strong>class of <strong>antidiabetic medication </strong>primarily used for the management of<strong> Type 2 diabetes mellitus. </strong>It works by<strong> decreasing hepatic glucose production </strong>and <strong>improving insulin sensitivity</strong>. It can<strong> increase risk of lactic acidosis </strong>particularly in patients with<strong> liver disease, renal disease </strong>and those <strong>pre-disposed to hypoxia</strong>.</span><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Renal function </strong>usually <strong>reduces in elderly patients, </strong>so it is <strong>avoided in elderly also</strong>.</span></em></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Advanced age:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Increases the risk </strong>because <strong>renal function </strong>typically <strong>declines with age</strong>, affecting <strong>metformin&rsquo;s clearance and increasing </strong>the likelihood of<strong> adverse effects </strong>including <strong>lactic acidosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Liver dysfunction:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A significant<strong> risk factor as liver disease </strong>can<strong> impair lactate clearance </strong>leading to <strong>higher lactate levels </strong>in the body.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Renal failure:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Directly linked to an<strong> increased risk </strong>due to the role of the <strong>kidneys in clearing metformin from the body</strong>; <strong>reduced renal function </strong>can lead to <strong>accumulation of the drug </strong>and an <strong>increased risk of lactic acidosis</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Risk factors </strong>for <strong>metformin induced lactic acidosis</strong></span></em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiorespiratory insufficiency leading to hypoxia (as in hypotensive state, cardiovascular disease, severe anemia) etc. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatic failure </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal failure </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alcoholics </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elderly</span></span></span></span></span></span></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 14712,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3747,
    "choices": [
      {
        "id": 14967,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 24-year-old woman with type 1 diabetes with two positive spot microalbuminuria tests 1 week apart</span></span></span></p>"
      },
      {
        "id": 14968,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old woman with type 1 diabetes with a blood glucose of 328 mg/dL and a positive spot microalbuminuria test</span></span></span></p>"
      },
      {
        "id": 14969,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old man with type 2 diabetes with a positive spot microalbuminuria test 1 week after starting a new exercise program</span></span></span></p>"
      },
      {
        "id": 14970,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old man with type 2 diabetes with two positive spot microalbuminuria tests 3 months apart&nbsp;</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following patients should be treated with either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker?</span></span></span></p>",
    "unique_key": "Q6591996",
    "question_audio": null,
    "question_video": null,
    "map_id": 36102,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) A 56-year-old man with type 2 diabetes with two positive spot microalbuminuria tests 3 months apart</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> use of ACE inhibitors or ARBs</strong> is indicated in patients with diabetes who exhibit <strong>persistent microalbuminuria, </strong>as this is a marker of <strong>early diabetic nephropathy. </strong>It is<strong> essential to confirm persistent microalbuminuria </strong>with at<strong> least two positive tests</strong> <strong>spaced 3 to 6</strong> months apart, in the absence of other conditions that might<strong> cause transient increases in albumin excretion.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The testing <strong>interval of 1 week</strong> is too soon for confirmation of <strong>persistent microalbuminuria. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The presence of<strong> severe hyperglycemia </strong>can <strong>transiently increase albumin excretion</strong>, potentially confounding the <strong>test result. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Vigorous exercise </strong>can also transiently <strong>increase albumin excretion,</strong> making the test result unreliable.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the management of<strong> diabetic nephropathy, ACE inhibitors or ARBs </strong>should be initiated in patients with <strong>type 2 diabetes</strong> who have <strong>confirmed persistent microalbuminuria, </strong>indicated by <strong>at least two positive microalbuminuria tests </strong>spaced<strong> 3 to 6 months </strong>apart, <strong>without </strong>the influence of <strong>confounding factors.</strong></span></span></span></p>",
    "correct_choice_id": 14970,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3676,
    "choices": [
      {
        "id": 14683,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Onapristone</span></span></span></p>"
      },
      {
        "id": 14684,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gestrinone</span></span></span></p>"
      },
      {
        "id": 14685,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mifepristone</span></span></span></p>"
      },
      {
        "id": 14686,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ulipristal</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drug is a selective progesterone receptor modulator that can be used as an emergency contraceptive even after 3 days of unprotected intercourse?</span></span></span></p>",
    "unique_key": "Q1504037",
    "question_audio": null,
    "question_video": null,
    "map_id": 36105,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Ulipristal</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>All the drugs </strong>given in the options are <strong>selective progesterone receptor modulators. Mifepristone and ulipristal </strong>are recommended for <strong>emergency contraception</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ulipristal and mifepristone </strong>can be used as <strong>emergency contraceptives</strong>.<strong> Mifepristone </strong>is effective if used <strong>within 72 hours </strong>of <strong>unprotected intercourse </strong>whereas<strong> ulipristal </strong>retains <strong>its efficacy </strong>till <strong>5 days of unprotected intercourse.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ulipristal </strong>is a recently approved &lsquo;<strong>selective progesterone receptor modulator&rsquo; (SPRM) </strong>for use as <strong>emergency contraceptive</strong>. It inhibits<strong> ovulation (by suppressing LH surge). </strong>In addition, its action on <strong>endometrium </strong>can <strong>interfere </strong>with <strong>implantation</strong>. The efficacy of <strong>ulipristal (30 mg) as emergency contraceptive </strong>is equal to that of <strong>levonorgestrel (1.5 mg) </strong>when taken within<strong> 72 hours of unprotected intercourse</strong>. It is <strong>effective up to 5 days </strong>of unprotected intercourse unlike other emergency contraceptives.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Onapristone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Although a <strong>selective progesterone receptor modulator</strong>, it is<strong> not </strong>indicated for <strong>emergency contraception.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Gestrinone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This <strong>SPRM is not </strong>commonly used for<strong> emergency contraception.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Mifepristone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Also an <strong>SPRM </strong>used for<strong> emergency contraception </strong>but is <strong>effective </strong>if used <strong>within 72 hours of unprotected intercourse</strong>, which is a<strong> shorter window compared to ulipristal.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ulipristal (30 mg) </strong>is effective as an <strong>emergency contraceptive up to 5 days </strong>after <strong>unprotected intercourse</strong>, making it a superior option for <strong>extending </strong>the<strong> window of opportunity for emergency contraception </strong>compared to other options like <strong>mifepristone and levonorgestrel.</strong></span></span></span></p>",
    "correct_choice_id": 14686,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 4252,
    "choices": [
      {
        "id": 16985,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liothyronine</span></span></span></p>"
      },
      {
        "id": 16986,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Levothyroxine</span></span></span></p>"
      },
      {
        "id": 16987,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carbimazole</span></span></span></p>"
      },
      {
        "id": 16988,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sodium iodide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 26-year-old pregnant lady was taking Antithyroid drug for Graves&rsquo; disease throughout the pregnancy. Following delivery infant was diagnosed to have &ldquo;Aplasia Cutis congenita.&rdquo; Most probable drug the female was taking during pregnancy was.</span></span></span></p>",
    "unique_key": "Q1188464",
    "question_audio": null,
    "question_video": null,
    "map_id": 36104,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Carbimazole</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Carbimazole,</strong> a<strong> thioamide antithyroid drug</strong>, has been associated with<strong> causing birth defects</strong> such as <strong>aplasia cutis congenita</strong> and <strong>choanal atresia</strong> when taken <strong>during pregnancy</strong>, particularly if<strong> administered </strong>during the<strong> first trimester.</strong> This drug <strong>inhibits </strong>the enzyme <strong>thyroid peroxidase,</strong> which is crucial for the <strong>synthesis of thyroid hormones</strong>. The<strong> inhibition </strong>of this enzyme can lead to <strong>decreased</strong> <strong>thyroid hormone production.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Carbimazole and methimazole</strong> use in <strong>pregnancy </strong>is associated with <strong>development of aplasia cutis and choanal atresia </strong>in the newborn baby.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Liothyronine:</strong> A <strong>synthetic form</strong> of <strong>triiodothyronine (T3)</strong>, <strong>not</strong> linked to congenital defects like <strong>aplasia cutis. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Levothyroxine:</strong> A <strong>synthetic form</strong> of <strong>thyroxine (T4), </strong>also<strong> not </strong>linked to <strong>congenital defects in infants. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Sodium Iodide:</strong> Used to<strong> correct iodine deficiency,</strong> <strong>not </strong>associated with causing <strong>aplasia cutis congenita.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thioamides:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs in this include <strong>propylthiouracil, carbimazole and methimazole.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These act by<strong> inhibiting the enzyme thyroid peroxidase</strong>. Later helps in <strong>formation</strong> of <strong>thyroid hormones. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most serious adverse effect of <strong>thioamides is agranulocytosis</strong></span><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">. </span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common adverse effect of these drugs is <strong>purpuric rash. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Cholestatic jaundice </strong>is common with <strong>methimazole. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Propylthiouracil</strong> causes<strong> hepatic dysfunction,</strong> especially in <strong>children &amp; pregnant women.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Methimazole and carbimazole </strong>are rarely associated with <strong>aplasia cutis and choanal atresia</strong> if given in the<strong> first trimester</strong> <strong>of pregnancy. </strong></span></span><strong> </strong></span></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 16987,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3940,
    "choices": [
      {
        "id": 15739,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">GnRH agonist</span></span></span></p>"
      },
      {
        "id": 15740,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen antagonist</span></span></span></p>"
      },
      {
        "id": 15741,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective estrogen receptor modulator</span></span></span></p>"
      },
      {
        "id": 15742,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective progesterone receptor modulator</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ulipristal is a relatively new drug being used by gynecologists. It acts as a?</span></span></span></p>",
    "unique_key": "Q4852686",
    "question_audio": null,
    "question_video": null,
    "map_id": 36123,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Selective progesterone receptor modulator</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ulipristal</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> acts as a <strong>Selective Progesterone Receptor Modulator (SPRM)</strong>. It is used in gynaecology for specific conditions such as the <strong>emergency contraception (30 mg single dose</strong> can be used up to <strong>120 hours of unprotected intercourse)</strong> and the treatment of <strong>moderate to severe symptoms of uterine fibroids</strong> in<strong> premenopausal women.</strong> As an<strong> SPRM,</strong> <strong>ulipristal</strong> works by <strong>modulating the</strong> <strong>progesterone receptors in the body,</strong> which can have <strong>both agonistic and antagonistic effects </strong>depending on the tissue. This action allows it to<strong> alter the endometrium,</strong> i<strong>nhibit or delay ovulation, </strong>and <strong>reduce the size </strong>and <strong>symptoms of uterine fibroids</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. GnRH agonist</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: GnRH agonists work by<strong> initially stimulating and then downregulating the production of gonadotropins (LH</strong> <strong>and FSH)</strong>, leading to a<strong> decrease in estrogen and testosterone production</strong>. Examples include <strong>leuprolide and goserelin</strong>. <strong>Ulipristal does</strong> <strong>not act </strong>through this<strong> mechanism.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Androgen antagonist</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Androgen antagonists <strong>block the effects of androgens (male hormones) at their receptor sites</strong>. They are used in conditions like<strong> prostate cancer and hirsutism in women.</strong> Ulipristal does not function as an androgen antagonist.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Selective estrogen receptor modulator</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: SERMs, such as<strong> tamoxifen or raloxifene,</strong> act on <strong>estrogen receptors</strong>, having <strong>agonistic or antagonistic effects depending on the target tissue</strong>. <strong>Ulipristal, </strong>however, specifically <strong>modulates progesterone receptors,</strong> <strong>not</strong> <strong>estrogen receptors.</strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective:</u></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ulipristal </strong>is a<strong> selective progesterone receptor modulator (SPRM)</strong> used in<strong> gynecology for emergency contraception </strong>and the treatment of<strong> uterine fibroids</strong>. Its unique <strong>action on progesterone receptors </strong>allows for <strong>versatile therapeutic effects</strong> in <strong>reproductive</strong> <strong>health.</strong></span></span></span></p>",
    "correct_choice_id": 15742,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3655,
    "choices": [
      {
        "id": 14599,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin</span></span></span></p>"
      },
      {
        "id": 14600,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vildagliptin</span></span></span></p>"
      },
      {
        "id": 14601,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"color:black\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Exenatidie</span></span></span></span></p>"
      },
      {
        "id": 14602,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old hypertensive patient with stage 5 chronic kidney disease was diagnosed recently with Type 2 diabetes mellitus. He does not want to take injectable drugs. Which of the following oral hypoglycemic agents will be preferred in this patient that does not require any dose modification in renal failure?</span></span></span></p>",
    "unique_key": "Q8631194",
    "question_audio": null,
    "question_video": null,
    "map_id": 36119,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Linagliptin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Linagliptin </strong>is a <strong>dipeptidyl peptidase-4 (DPP-4) inhibitor </strong>that is preferred in patients with <strong>renal impairment</strong>, including those with <strong>stage 5 CKD</strong>, because it <strong>does not require dose adjustments</strong>. Linagliptin&#39;s pharmacokinetics are such that it is <strong>less dependent on renal excretion compared </strong>to <strong>other DPP-4 inhibitors, </strong>making it a <strong>safer </strong>option for patients with significant <strong>renal dysfunction</strong>. This characteristic allows for the management of<strong> Type 2 diabetes in patients with varying degrees of kidney disease </strong>without the need to modify the dose, thus simplifying<strong> treatment and reducing </strong>the <strong>risk of drug accumulation and adverse effects.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Vildagliptin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While<strong> vildagliptin </strong>is another<strong> DPP-4 inhibitor, </strong>it<strong> requires dose adjustments </strong>in patients with <strong>renal impairment</strong>, making it<strong> less ideal than linagliptin </strong>for patients with <strong>stage 5 CKD</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Exenatide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Exenatide </strong>is <strong>not </strong>an <strong>oral hypoglycemic agent </strong>but an <strong>injectable glucagon-like peptide-1 (GLP-1) receptor agonist. </strong>It also <strong>requires dose adjustments </strong>in patients with <strong>renal impairment </strong>and would<strong> not </strong>be suitable for a patient who prefers to avoid injectable drugs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Traditionally, <strong>metformin </strong>has been <strong>contraindicated in patients </strong>with significant<strong> renal impairment due to the risk of lactic acidosis</strong>. Although recent guidelines have provided<strong> more lenient criteria </strong>for its use in patients with <strong>moderate renal impairment</strong>, it is generally <strong>avoided in stage 5 CKD</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Linagliptin, a DPP-4 inhibitor, </strong>is a preferred <strong>oral hypoglycemic agent </strong>for patients with <strong>Type 2 diabetes and severe renal impairment</strong>, as it<strong> does not </strong>require dose adjustments in<strong> renal failure</strong>, simplifying <strong>diabetes management </strong>in this population.</span></span></span></p>",
    "correct_choice_id": 14599,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3962,
    "choices": [
      {
        "id": 15827,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liothyronine</span></span></span></p>"
      },
      {
        "id": 15828,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">L-Thyroxine</span></span></span></p>"
      },
      {
        "id": 15829,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carbimazole</span></span></span></p>"
      },
      {
        "id": 15830,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Steroids</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presented with swelling in the neck as shown in figure. She also complained of decreased appetite, fatigue, cold intolerance, and menstrual irregularities. She gained 10 kg weight in the last 4-5 months. Thyroid function tests showed normal T4 levels but elevated TSH levels. The patient should be treated with. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture22.jpg\" style=\"height:227px; width:300px\" /></p>",
    "unique_key": "Q3132953",
    "question_audio": null,
    "question_video": null,
    "map_id": 36136,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. L-Thyroxine </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s clinical presentation and laboratory findings suggest hypothyroidism, characterized by swelling in the neck (likely indicating goitre), symptoms of decreased appetite, fatigue, cold intolerance, menstrual irregularities, weight gain, normal T4 levels, but elevated TSH levels. The appropriate treatment in this case would be L-thyroxine.</span></span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">L-Thyroxine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> (levothyroxine) is the standard treatment for hypothyroidism. It is a synthetic form of thyroxine (T4), the hormone that is deficient in hypothyroidism. Supplementation with L-Thyroxine helps to normalize thyroid hormone levels, thereby alleviating</strong> the symptoms of <strong>hypothyroidism</strong>, including those described for the <strong>patient. </strong>The<strong> goal of treatmen</strong>t is to <strong>normalize the patient&#39;s TSH levels and resolve symptoms.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Liothyronine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Liothyronine is a<strong> synthetic form of triiodothyronine (T3)</strong>. While it can be <strong>used </strong>in certain <strong>specific situations,</strong> such as in<strong> combination therapy with levothyroxine </strong>for some patients,<strong> L-Thyroxine </strong>remains the <strong>primary treatment</strong> for <strong>hypothyroidism</strong> due to its<strong> stability, longer half-life, and more consistent serum levels.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Carbimazole</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Carbimazole is used to <strong>treat hyperthyroidism, </strong>not hypothyroidism. It works by <strong>inhibiting the synthesis of</strong> <strong>thyroid hormones,</strong> which would be <strong>contraindicated in a patient </strong>already showing <strong>signs of low thyroid hormone activity.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Steroids</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Steroids are <strong>not a primary treatment for primary hypothyroidism</strong>. They can be used in <strong>specific cases of</strong> t<strong>hyroiditis</strong> where<strong> inflammation is a significant </strong>component, but they would <strong>not be the first choice i</strong>n typical hypothyroidism treatment.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with <strong>hypothyroidism </strong>indicated by symptoms of<strong> thyroid hormone deficiency </strong>and<strong> elevated TSH levels</strong> with <strong>normal T4, L-Thyroxine </strong>is the appropriate <strong>treatment </strong>to<strong> normalize thyroid function and alleviate symptoms.</strong></span></span></p>",
    "correct_choice_id": 15828,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 3941,
    "choices": [
      {
        "id": 15743,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">To be given an empty stomach with a full glass of water.</span></span></span></p>"
      },
      {
        "id": 15744,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Must be taken along with food.</span></span></span></p>"
      },
      {
        "id": 15745,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Should be stopped if features of gastritis develop.</span></span></span></p>"
      },
      {
        "id": 15746,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Should be stopped if bone pains occur.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">What are the appropriate instructions to be given while prescribing bisphosphonates to a patient? </span></span></span></p>",
    "unique_key": "Q4977515",
    "question_audio": null,
    "question_video": null,
    "map_id": 36124,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. To be given empty stomach with a glass of water</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bisphosphonates</strong> should be taken on an <strong>empty stomach with a full glass of water </strong>to enhance <strong>absorption</strong>. Patients are advised to remain <strong>upright (sitting or standing) for at least 30 to 60 minutes </strong>after taking the medication. This precaution <strong>helps to prevent</strong> <strong>esophageal irritation</strong> and <strong>ensure the drug moves quickly to the stomach, reducing the risk of gastroesophageal reflux </strong>and <strong>esophagitis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Must be taken along with food</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This instruction is<strong> incorrect</strong> because<strong> food</strong> significantly <strong>decreases the absorption of</strong> <strong>bisphosphonates.</strong> They <strong>should be taken</strong> on an<strong> empty stomach.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Should be stopped if features of gastritis develop</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While patients should report any<strong> severe gastrointestinal symptoms</strong> to their <strong>healthcare provider,</strong> the<strong> decision to stop </strong>the medication should be made<strong> by the physician.</strong> Management strategies may include evaluating the patient&#39;s condition, considering an <strong>alternative bisphosphonate formulation (e.g., intravenous),</strong> or<strong> addressing</strong> the <strong>gastritis </strong>while<strong> continuing treatment as necessary.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Should be stopped if bone pains occur</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bone pain can be a <strong>side effect of bisphosphonates, </strong>but patients <strong>should consult</strong> their <strong>healthcare provider </strong>before <strong>stopping the medication</strong>. The provider may assess the <strong>cause of bone pain</strong> and consider <strong>alternative</strong> <strong>treatments or supportive</strong> measures rather than<strong> immediately discontinuing the bisphosphonate.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When prescribing<strong> bisphosphonates,</strong> it is<strong> crucial to instruct patients</strong> to take the medication on an<strong> empty stomach </strong>with <strong>plenty of</strong> <strong>water </strong>and to remain<strong> upright for</strong> at<strong> least 30 to 60 minutes</strong> afterward to <strong>prevent gastrointestinal complications</strong> and ensure <strong>optimal</strong> <strong>absorption of the drug.</strong></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span> </span></span></span></p>",
    "correct_choice_id": 15743,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 4094,
    "choices": [
      {
        "id": 16355,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometriosis</span></span></span></p>"
      },
      {
        "id": 16356,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Male infertility</span></span></span></p>"
      },
      {
        "id": 16357,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Precocious puberty</span></span></span></p>"
      },
      {
        "id": 16358,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prostatic carcinoma</span></span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-pulsatile administration of GnRH agonist can be used in all of the following conditions except.</span></span></p>",
    "unique_key": "Q2016109",
    "question_audio": null,
    "question_video": null,
    "map_id": 36137,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Male infertility </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">For treatment of <strong>male infertility,</strong> <strong>GnRH agonists</strong> need to be given in <strong>pulsatile manner. </strong>For all other conditions given in the options, <strong>GnRH agonists </strong>are administered in a <strong>non-pulsatile continuous fashion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gonadotropin-Releasing Hormone (GnRH) and Its Analogs</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>GnRH is a decapeptide</strong> that stimulates <strong>gonadotropin release</strong> when it is secreted in a <strong>pulsatile pattern by the</strong> <strong>hypothalamus.&nbsp;</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Leuprolide&nbsp;</strong>was the <strong>first long-acting GnRH agonist. Other</strong> long-acting GnRH agonists include<strong>&nbsp;goserelin,&nbsp;histarelin,</strong> <strong>busurelin,&nbsp;nafarelin,&nbsp;and&nbsp;triptorelin.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Steady dosing (non-pulsatile) with these GnRH agonists inhibits gonadotropin </strong>release by <strong>downregulating GnRH</strong> receptors in th<strong>e pituitary cells </strong>that normally release <strong>gonadotropins. </strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulsatile administration of GnRH agonists is used for:</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypogonadotropic hypogonadism.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infertility in both males (oligozoospermia) and females (anovulatory infertility)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Delayed puberty</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Continuous GnRH agonist treatment is used:</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">To suppress <strong>endogenous gonadotropin secretion </strong>in <strong>women</strong> undergoing<strong> ovulation induction with gonadotropin</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In women with <strong>gynecologic disorders</strong> that benefit from <strong>ovarian suppression (e.g., endometriosis, uterine leiomyomata)</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In men with <strong>advanced prostate cancer</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In children with <strong>central precocious puberty.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> first few days</strong> of <strong>continuous administration </strong>can<strong> temporarily exacerbate </strong>the condition. This is known as<strong> flare up reaction.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Endometriosis</strong>: <strong>Continuous GnRH agonist</strong> treatment can <strong>suppress ovarian function </strong>and is beneficial in conditions like <strong>endometriosis. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Precocious Puberty</strong>:<strong> GnRH agonists</strong> are used to suppress<strong> premature gonadotropin secretion</strong> in children with <strong>central</strong> <strong>precocious puberty. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Prostatic Carcinoma</strong>: In men with <strong>advanced prostate cancer,</strong> continuous<strong> GnRH agonist </strong>treatment is used to<strong> suppress</strong> <strong>androgen production.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Non-pulsatile administration of GnRH agonists</strong> is utilized for conditions requiring <strong>suppression of gonadotropin secretion</strong>, such as <strong>endometriosis, prostatic carcinoma, and precocious puberty, </strong>but<strong> not </strong>for <strong>male infertility</strong>, which requires <strong>pulsatile treatment</strong> to stimulate <strong>gonadotropin release.</strong></span></span></span></span></span></span></p>",
    "correct_choice_id": 16356,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3753,
    "choices": [
      {
        "id": 14991,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
      },
      {
        "id": 14992,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin</span></span></span></p>"
      },
      {
        "id": 14993,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol</span></span></span></p>"
      },
      {
        "id": 14994,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient of diabetes mellitus and hypertension is admitted in the hospital with features of sepsis and there is increase in serum creatinine levels. Which of the following drugs should be stopped? </span></span></span></p>",
    "unique_key": "Q8843992",
    "question_audio": null,
    "question_video": null,
    "map_id": 36118,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Metformin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> should be<strong> stopped </strong>in this patient&rsquo;s case <strong>due to the development of sepsis and the increase in serum creatinine levels, </strong>which<strong> indicate an acute deterioration in renal function</strong>. Metformin is<strong> contraindicated </strong>in conditions that <strong>can impair renal function or lead to renal failure </strong>because of the <strong>risk of lactic acidosis</strong>, a rare but<strong> serious complication a</strong>ssociated with <strong>metformin accumulation </strong>in the body. In the setting of sepsis, which can further compromise <strong>renal function and increase the risk of lactic acidosis</strong>, <strong>discontinuation of metformin</strong> is advised until the patient&rsquo;s <strong>renal function stabilizes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Insulin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Insulin may still be needed to manage the patient&#39;<strong>s blood glucose levels, </strong>especially in the<strong> stress of sepsis</strong>, which can cause<strong> hyperglycemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Metoprolol</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It is a<strong> lipid soluble beta-blocker </strong>used to manage<strong> hypertension </strong>and other <strong>cardiovascular conditions</strong>. It is <strong>safe </strong>in <strong>renal failure</strong>.<strong> Beta blockers</strong> which should be <strong>avoided in renal failure are atenolol, nadolol and sotalol (ANS) </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Linagliptin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A<strong> DPP-4 inhibitor </strong>used in the management of<strong> type 2 diabetes. </strong>It is considered safe in patients with <strong>renal impairment </strong>unlike other drugs in this group. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with <strong>diabetes and renal impairment, </strong>especially in <strong>acute settings such as sepsis,</strong><em> <strong>metformin </strong></em>should be discontinued to prevent the <strong>risk of lactic acidosis.</strong> It is important to<strong> monitor renal function </strong>closely and adjust medication as needed based on the patient&rsquo;s <strong>current health status.</strong></span></span></p>",
    "correct_choice_id": 14991,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 4245,
    "choices": [
      {
        "id": 16957,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cortisol</span></span></span></p>"
      },
      {
        "id": 16958,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prednisolone</span></span></span></p>"
      },
      {
        "id": 16959,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Betamethasone</span></span></span></p>"
      },
      {
        "id": 16960,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrocortisone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Long term steroid therapy can lead to suppression of hypothalamic pituitary-adrenal axis. It can be overcome by using alternate day therapy with corticosteroids. Which of the following steroids is unsuitable for alternate day therapy for such purpose? </span></span></span></p>",
    "unique_key": "Q8334869",
    "question_audio": null,
    "question_video": null,
    "map_id": 36112,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Betamethasone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Betamethasone</strong> is a <strong>long-acting corticosteroid</strong> with a <strong>duration of action</strong> that generally exceeds <strong>48 hours. </strong>Because of its <strong>long</strong> d<strong>uration of action, </strong>betamethasone is<strong> unsuitable </strong>for <strong>alternate day</strong> therapy intended to <strong>minimize the suppression of the</strong> <strong>hypothalamic-pituitary-adrenal (HPA) axis.</strong> Alternate day therapy is designed to allow the <strong>HPA axis </strong>to <strong>recover on the off days,</strong> which is <strong>more feasible with corticosteroids</strong> that have a <strong>shorter duration of action.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Cortisol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Cortisol,</strong> also known as <strong>hydrocortisone</strong> when used as a medication, has a<strong> short duration of action, </strong>making it suitable for <strong>alternate day therapy.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Prednisolone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Prednisolone is an <strong>intermediate-acting corticosteroid </strong>that is commonly used in <strong>alternate day therapy to</strong> <strong>reduce HPA axis suppression.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hydrocortisone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hydrocortisone is <strong>essentially synthetic cortisol</strong> with a <strong>short duration of action</strong>, suitable for <strong>alternate day</strong> therapy to <strong>minimize HPA axis suppression.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Betamethasone&#39;s long duration of action</strong> makes it inappropriate for<strong> alternate day therapy </strong>designed to <strong>mitigate HPA axis</strong> <strong>suppression, </strong>unlike <strong>shorter-acting steroids like hydrocortisone</strong>, which are <strong>better </strong>suited for such <strong>treatment schedules.</strong></span></span></span></p>",
    "correct_choice_id": 16959,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 4113,
    "choices": [
      {
        "id": 16431,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin:&nbsp; Treatment of diabetes insipidus.</span></span></span></p>"
      },
      {
        "id": 16432,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Octreotide:&nbsp; Treatment of bleeding esophageal varices.</span></span></span></p>"
      },
      {
        "id": 16433,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oxytocin:&nbsp; Induction of labor.</span></span></span></p>"
      },
      {
        "id": 16434,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Goserelin:&nbsp; Growth hormone deficiency</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following agents are correctly paired with an appropriate clinical use of the drug except.</span></span></span></p>",
    "unique_key": "Q9557041",
    "question_audio": null,
    "question_video": null,
    "map_id": 36110,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Goserelin: Growth hormone deficiency</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Goserelin </strong>is a<strong> gonadotropin-releasing hormone (GnRH) agonist,</strong> <strong>not </strong>used for the treatment of<strong> growth hormone deficiency</strong>. It is commonly used in the<strong> treatment of hormone-sensitive cancers </strong>such as <strong>prostate cancer in men and breast cancer in premenopausal women</strong>, as well as for<strong> endometriosis </strong>and in assisted reproduction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Desmopressin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Desmopressin is a <strong>synthetic analogue of vasopressin</strong> and is drug of choice for the treatment of <strong>central</strong> <strong>diabetes insipidus and nocturnal enuresis.</strong> It is also used for managing<strong> bleeding</strong> in patients<strong> with von Willebrand disease and mild hemophilia A </strong>due to its ability to<strong> increase the levels of von Willebrand factor and factor VIII</strong>.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Octreotide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Octreotide is a<strong> somatostatin analogue </strong>that can <strong>reduce portal blood flow </strong>and is <strong>used</strong> in the management of <strong>bleeding esophageal varices</strong> as an adjunct to specific treatments like <strong>endoscopic band ligation or sclerotherapy.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Oxytocin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Oxytocin is a <strong>peptide hormone </strong>and is<strong> drug of choice </strong>to<strong> induce labor in pregnant women</strong> who are <strong>at or near</strong> term when there is a medical reason for<strong> inducing labor, or to strengthen labor contractions during childbirth.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Goserelin </strong>is a <strong>GnRH agonist </strong>used primarily in the treatment of<strong> hormone-sensitive cancers </strong>and is<strong> not indicated for growth hormone</strong> <strong>deficiency,</strong> which would require<strong> growth hormone therapy </strong>or other <strong>specific treatments</strong> related to<strong> growth hormone biosynthesis or</strong> <strong>action.</strong></span></span></p>",
    "correct_choice_id": 16434,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3682,
    "choices": [
      {
        "id": 14707,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carbimazole</span></span></span></p>"
      },
      {
        "id": 14708,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lugol&rsquo;s iodine</span></span></span></p>"
      },
      {
        "id": 14709,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propylthiouracil</span></span></span></p>"
      },
      {
        "id": 14710,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methimazole</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old patient diagnosed with Graves&#39; disease is under consideration for antithyroid therapy. The patient has a history of atrial fibrillation and is currently on beta-blockers. Given the patient&#39;s clinical profile and the need to rapidly achieve euthyroidism while minimizing cardiac complications, the healthcare provider is exploring antithyroid medications that can not only reduce thyroid hormone production but also inhibit the peripheral conversion of thyroxine (T4) to the more active triiodothyronine (T3). Which of the following antithyroid medications can inhibit the peripheral conversion of T4 to T3?</span></span></span></p>",
    "unique_key": "Q6364365",
    "question_audio": null,
    "question_video": null,
    "map_id": 36122,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Propylthiouracil</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Propylthiouracil (PTU) </strong>is an <strong>antithyroid </strong>medication that<strong> not </strong>only <strong>inhibits thyroid hormone synthesis </strong>but also has the unique ability among <strong>antithyroid drugs to inhibit the peripheral conversion of thyroxine (T4) </strong>to the <strong>more active form</strong>, <strong>triiodothyronine (T3). </strong>This <strong>dual action </strong>can be particularly beneficial in managing <strong>hyperthyroidism </strong>in patients where <strong>rapid control of thyroid hormone effects </strong>is crucial, such as those with <strong>cardiac complications like atrial fibrillation. </strong>PTU&#39;s ability to<strong> reduce T3 levels </strong>can lead to a <strong>quicker normalization of thyroid hormone effects </strong>on the<strong> heart and other organs.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Carbimazole</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Carbimazole is a<strong> pro-drug </strong>that is<strong> converted to methimazole in the body</strong>. It <strong>inhibits thyroid hormone synthesis </strong>but <strong>does not </strong>significantly <strong>inhibit the peripheral conversion of T4 to T3.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Lugol&rsquo;s iodine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Lugol&#39;s iodine can quickly<strong> reduce the size and vascularity of the thyroid gland </strong>and <strong>inhibit </strong>the release of <strong>thyroid hormones</strong>, but it does not have a direct inhibitory effect on the peripheral conversion of T4 to T3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Methimazole</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Methimazole<strong> inhibits thyroid hormone synthesis </strong>by blocking the<strong> iodination of tyrosine </strong>residues in <strong>thyroglobulin</strong>. Like<strong> carbimazole</strong>, it<strong> does not </strong>significantly <strong>inhibit the peripheral conversion of T4 to T3.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture3.jpg\" style=\"height:562px; width:1000px\" /></span></span></u></strong></p>",
    "correct_choice_id": 14709,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 4256,
    "choices": [
      {
        "id": 17001,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carcinoma of ovary</span></span></span></p>"
      },
      {
        "id": 17002,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometrial carcinoma</span></span></span></p>"
      },
      {
        "id": 17003,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast carcinoma</span></span></span></p>"
      },
      {
        "id": 17004,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic myeloid leukemia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A lady who was treated for breast cancer is on long-term tamoxifen therapy as she is ER-positive. Drug tamoxifen can increase the risk for which of the following cancers?<strong> </strong></span></span></span></p>",
    "unique_key": "Q4932986",
    "question_audio": null,
    "question_video": null,
    "map_id": 36114,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Endometrial carcinoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tamoxifen </strong>was the<strong> first&nbsp;selective estrogen receptor modulator (SERM)&nbsp;</strong>to be introduced. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen is extensively used in the<strong> palliative treatment of breast cancer in postmenopausal women </strong>and is approved for<strong> chemoprevention of breast cancer</strong> in<strong> high-risk women. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen has <strong>estrogen agonistic action on bone and blood. Prevention </strong>of the expected <strong>loss of lumbar spine bone</strong> <strong>density </strong>and <strong>plasma lipid changes</strong> consistent with a <strong>reduction in the risk for atherosclerosis </strong>have also been reported in <strong>tamoxifen-treated patients </strong>following <strong>spontaneous or surgical menopause. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">However, this <strong>estrogen agonist activity on uterus</strong> may <strong>increase the risk of endometrial cancer.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a <strong>nonsteroidal agent</strong> that is given<strong> orally. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen has an initial <strong>half-life of 7&ndash;14 hours </strong>in circulation and is predominantly <strong>excreted by the liver. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Toremifene</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;is a <strong>structurally similar compound</strong> with very <strong>similar properties, indications, and toxicities.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Carcinoma of the ovary:</strong> There is<strong> no </strong>established link between <strong>tamoxifen use</strong> and an increased risk of ovarian cancer. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Breast carcinoma:</strong> <strong>Tamoxifen</strong> is actually used to<strong> reduce the risk of breast cancer</strong> recurrence. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Chronic myeloid leukemia:</strong> There is<strong> no</strong> evidence to suggest that<strong> tamoxifen increases the risk of developing leukemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">While<strong> tamoxifen</strong> is effective in <strong>treating and preventing breast cancer</strong> recurrence in<strong> ER-positive patients</strong> by <strong>acting as an estrogen</strong> <strong>antagonist on breast tissue, </strong>its <strong>agonistic effects on the uterus</strong> can <strong>increase </strong>the risk of<strong> endometrial carcinoma, </strong>necessitating <strong>careful</strong> <strong>monitoring and evaluation during therapy.</strong></span></span></span></p>",
    "correct_choice_id": 17002,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 4096,
    "choices": [
      {
        "id": 16363,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></span></span></p>"
      },
      {
        "id": 16364,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
      },
      {
        "id": 16365,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
      },
      {
        "id": 16366,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glipizide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drug is approved for treatment of type 1 as well as type 2 diabetes mellitus?</span></span></span></p>",
    "unique_key": "Q8022585",
    "question_audio": null,
    "question_video": null,
    "map_id": 36106,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Pramlintide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is an <strong>amylin analogue</strong> approved for use in<strong> both type 1 and type 2 diabetes mellitus.</strong> It is used as an <strong>adjunct treatment</strong> for patients who are already using <strong>insulin </strong>but have <strong>not achieved</strong> desired <strong>glucose control. Pramlintide </strong>works by<strong> mimicking the</strong> <strong>actions of amylin&mdash;a hormone </strong>that is<strong> co-secreted </strong>with<strong> insulin from pancreatic &beta;-cells</strong>&mdash;thereby <strong>slowing gastric emptying, promoting</strong> <strong>satiety,</strong> and<strong> preventing postprandial spikes in blood glucose levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Primarily used in the treatment of <strong>type 2 diabetes mellitus,</strong> metformin is a<strong> biguanide </strong>that <strong>reduces hepatic</strong> <strong>glucose production and improves insulin sensitivity. </strong>It is <strong>not used </strong>in the treatment of <strong>type 1 diabetes </strong>because type 1 diabetes involves <strong>insulin deficiency, </strong>and<strong> metformin does not replace insulin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Sitagliptin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A <strong>dipeptidyl peptidase-4 (DPP-4) inhibitor</strong> used in the treatment of <strong>type 2 diabetes</strong>. It works by<strong> increasing</strong> <strong>incretin levels</strong>, which <strong>inhibit glucagon release and increase insulin secretion </strong>in a <strong>glucose-dependent</strong> manner.<strong> Sitagliptin </strong>is <strong>not</strong> approved for use in<strong> type 1 diabetes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Glipizide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A <strong>sulfonylurea</strong> used in the treatment of <strong>type 2 diabetes</strong>. It stimulates the <strong>release of insulin from pancreatic &beta;-cells</strong>. Because individuals with <strong>type 1 diabetes</strong> have little to <strong>no insulin production, sulfonylureas like glipizide </strong>are not effective for<strong> type 1 diabetes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Pramlintide</strong> is approved for<strong> both type 1 and type 2 diabetes </strong>as an <strong>adjunct to insulin therapy </strong>due to its role in <strong>modulating gastric</strong> <strong>emptying and blood glucose levels post meals.</strong></span></span> <span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></span></span></span></p>",
    "correct_choice_id": 16363,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3700,
    "choices": [
      {
        "id": 14779,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Milnacipran</span></span></span></p>"
      },
      {
        "id": 14780,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teriparatide</span></span></span></p>"
      },
      {
        "id": 14781,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Strontium ranelate</span></span></span></p>"
      },
      {
        "id": 14782,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs are used in treatment of osteoporosis except.</span></span></span></p>",
    "unique_key": "Q9494581",
    "question_audio": null,
    "question_video": null,
    "map_id": 36132,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Milnacipran</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Milnacipran</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is not used in the treatment of <strong>osteoporosis</strong>. It is a<strong> serotonin&ndash;norepinephrine reuptake inhibitor (SNRI)</strong> primarily used in the management of <strong>fibromyalgia and depression.</strong> It has <strong>no role</strong> in the management or treatment of <strong>osteoporosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Teriparatide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Teriparatide is a <strong>recombinant form of parathyroid hormone</strong> used in the treatment of<strong> osteoporosis.</strong> It stimulates<strong> new bone formation </strong>by acting on <strong>osteoblasts</strong>, making it effective in <strong>reducing the risk of fractures </strong>in patients with <strong>osteoporosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Strontium ranelate</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Strontium ranelate is a medication <strong>used to treat severe osteoporosis in postmenopausal women</strong> and <strong>men at high risk of fractures</strong>. It works by simultaneously <strong>decreasing bone resorption and increasing bone formation.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Denosumab</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Denosumab is a <strong>monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-B</strong> <strong>Ligand)</strong>, a protein that<strong> acts</strong> as the <strong>primary signal for bone removal</strong>. <strong>By inhibiting RANKL,</strong> denosumab <strong>decreases bone resorption and</strong> <strong>increases bone mass and strength</strong> in patients with osteoporosis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs Used for Osteoporosis </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture6.jpg\" style=\"height:226px; width:1000px\" /></p>",
    "correct_choice_id": 14779,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 4107,
    "choices": [
      {
        "id": 16407,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Steroids</span></span></span></p>"
      },
      {
        "id": 16408,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate</span></span></span></p>"
      },
      {
        "id": 16409,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyroxine</span></span></span></p>"
      },
      {
        "id": 16410,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heparin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old postmenopausal woman presents to the clinic for a routine health check-up. She is concerned about osteoporosis, as her mother had a hip fracture at the age of 70. She has been on prednisone for the past year for rheumatoid arthritis and is also taking levothyroxine for hypothyroidism. She recently read about the risks of long-term medication use and osteoporosis. She inquiries about her medications and whether any of them could contribute to bone density loss. Which of her current medications is not associated with an increased risk of osteoporosis?</span></span></span></p>",
    "unique_key": "Q9588226",
    "question_audio": null,
    "question_video": null,
    "map_id": 36108,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Alendronate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Alendronate is a bisphosphonate</strong> that is actually used to <strong>treat and prevent osteoporosis, </strong>not cause it. It works by<strong> inhibiting</strong> <strong>osteoclast-mediated bone resorption,</strong> leading to an overall<strong> increase in bone mass and strength.</strong> This medication is commonly prescribed for<strong> postmenopausal women at risk of osteoporosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Steroids:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Long-term use of steroids,</strong> such as<strong> prednisone, </strong>is known to <strong>cause bone density loss and increase the risk of</strong> <strong>osteoporosis</strong> due to their<strong> impact on bone turnover and calcium absorption.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Thyroxine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Excessive levels of thyroid hormone</strong>, whether from <strong>hyperthyroidism or over-replacement</strong> with <strong>levothyroxine,</strong> can lead to<strong> increased bone resorption and a higher risk of osteoporosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Heparin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Long-term use of heparin</strong> can interfere with <strong>bone formation and increase the risk of osteoporosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Alendronate</strong> is used to <strong>treat and prevent osteoporosis, </strong>whereas <strong>steroids, excess thyroxine, and heparin</strong> can contribute to the <strong>development of osteoporosis.</strong></span></span></span></span></span></p>",
    "correct_choice_id": 16408,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3621,
    "choices": [
      {
        "id": 14463,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin</span></span></span></p>"
      },
      {
        "id": 14464,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leuprolide</span></span></span></p>"
      },
      {
        "id": 14465,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazide diuretics</span></span></span></p>"
      },
      {
        "id": 14466,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Drug of choice for central diabetes Insipidus is.</span></span></span>\u200b\u200b\u200b\u200b</p>",
    "unique_key": "Q7559444",
    "question_audio": null,
    "question_video": null,
    "map_id": 36116,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A. Desmopressin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Desmopressin</strong> is the<strong> drug of choice </strong>for the treatment of <strong>central diabetes insipidus. </strong>Central diabetes insipidus is a condition where the<strong> pituitary gland fails</strong> to secrete adequate amounts of <strong>antidiuretic hormone (ADH), </strong>also known as <strong>vasopressin, </strong>which <strong>helps</strong> the <strong>kidneys </strong>manage the<strong> amount of water in the body.</strong> <strong>Desmopressin</strong> is a <strong>synthetic analogue of vasopressin. </strong></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It acts selectively at<strong> V2</strong> <strong>receptors</strong> to <strong>increase urine concentration and decrease urine flow </strong>in a <strong>dose dependent manner.</strong> It is more resistant to degradation than<strong> endogenous vasopressin (Arginine vasopressin; AVP) </strong>and has a <strong>three to fourfold longer duration of action</strong>. <strong>Desmopressin </strong>can be given by <strong>IV or SC injection, nasal inhalation, or oral tablet.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">. <strong>Leuprolide</strong>: Leuprolide is a <strong>gonadotropin-releasing hormone (GnRH) agonist </strong>used in the treatment of <strong>hormone-sensitive</strong> conditions like<strong> prostate cancer, endometriosis, and uterine fibroids.</strong> It is <strong>not </strong>used in the treatment of<strong> diabetes insipidus</strong> as it does <strong>not </strong>influence <strong>ADH secretion or action.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C</span></strong><span style=\"font-size:12.0pt\">. <strong>Thiazide Diuretics</strong>: Thiazide diuretics are used in the treatment of <strong>both nephrogenic diabetes insipidus </strong>(a form of the condition caused by the <strong>kidneys&#39; inability to respond to ADH)</strong> as well as <strong>central (neurogenic) diabetes insipidus.</strong> They are drug of <strong>choice for nephrogenic diabetes insipidus</strong> but <strong>not central diabetes insipidus. </strong>Thiazides <strong>reduce urine volume </strong>in diabetes insipidus by <strong>increasing water absorption in the distal tubules </strong>of the kidney, but they <strong>do not</strong> address the <strong>lack of ADH production in central</strong> <strong>diabetes insipidus.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D</span></strong><span style=\"font-size:12.0pt\">. <strong>Insulin</strong>: Insulin is used in the<strong> treatment of diabetes mellitus, </strong>a completely<strong> different </strong>condition <strong>from diabetes insipidus.</strong> <strong>Diabetes mellitus</strong> involves problems with<strong> blood sugar control </strong>due to <strong>insufficient insulin production (Type 1 diabetes) </strong>or <strong>insulin</strong> <strong>resistance (Type 2 diabetes)</strong>. It <strong>does not </strong>directly affect the <strong>balance of water in the body, nor </strong>is it relevant to the <strong>treatment</strong> of <strong>diabetes insipidus.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/01/picture1_dSWDtRK.jpg\" style=\"height:176px; width:1000px\" /></span></span></u></strong></p>",
    "correct_choice_id": 14463,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3625,
    "choices": [
      {
        "id": 14479,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metyrapone</span></span></span></p>"
      },
      {
        "id": 14480,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole</span></span></span></p>"
      },
      {
        "id": 14481,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aminoglutethimide</span></span></span></p>"
      },
      {
        "id": 14482,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the above</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs can be used for medical adrenalectomy?</span></span></span></p>",
    "unique_key": "Q8360246",
    "question_audio": null,
    "question_video": null,
    "map_id": 36117,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. All the above</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Medical adrenalectomy </strong>refers to the pharmacological <strong>suppression of adrenal gland function,</strong> typically aimed at <strong>reducing </strong>the production of<strong> adrenal steroids</strong>. This approach is often<strong> used </strong>in the <strong>management of Cushing&#39;s syndrome, </strong>where there is an <strong>overproduction of cortisol</strong> by the <strong>adrenal glands. </strong>All the listed drugs, <strong>Metyrapone, Ketoconazole, and Aminoglutethimide,</strong> can be used for<strong> medical adrenalectomy.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Metyrapone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Inhibits 11-&beta;-hydroxylase,</strong> an enzyme critical in the<strong> final step of cortisol synthesis</strong> in the<strong> adrenal cortex</strong>. By <strong>inhibiting this enzyme</strong>, <strong>metyrapone</strong> effectively <strong>reduces cortisol</strong> production.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Ketoconazole:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Is an<strong> antifungal medication </strong>that also has <strong>potent inhibitory effects</strong> on <strong>adrenal and gonadal steroid synthesis.</strong> It works by <strong>inhibiting several cytochrome P450 enzymes</strong> involved in <strong>steroid synthesis,</strong> thereby <strong>reducing cortisol levels.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Aminoglutethimide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Inhibits </strong>the enzyme <strong>P450scc (cholesterol side-chain cleavage enzyme),</strong> which is involved in the<strong> first</strong> <strong>step of cortisol synthesis</strong>, converting <strong>cholesterol to pregnenolone</strong>. This results in a<strong> decrease in the production</strong> of all <strong>adrenal</strong> <strong>steroids</strong>, including <strong>cortisol.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">DRUGS INHIBITING THE FORMATION OF ADRENAL STEROIDS</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These <strong>drugs</strong> can be used for <strong>medical adrenalectomy.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metyrapone</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aminoglutethimide</span></span></span></li>\r\n\t<li><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mitotane</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/01/picture2.jpg\" style=\"height:494px; width:600px\" /></span></span></p>",
    "correct_choice_id": 14482,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3677,
    "choices": [
      {
        "id": 14687,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Posterior subcapsular cataract</span></span></span></p>"
      },
      {
        "id": 14688,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Iridocyclitis</span></span></span></p>"
      },
      {
        "id": 14689,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Open angle glaucoma</span></span></span></p>"
      },
      {
        "id": 14690,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Retinoblastoma</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old patient with a history of chronic uveitis has been on corticosteroid eye drops for an extended period as part of the treatment regimen. During a routine follow-up at the ophthalmology clinic, the ophthalmologist evaluates the patient for potential long-term complications associated with the prolonged use of corticosteroid eye drops. Which of the following is a complication of prolonged use of corticosteroid eye drops?</span></span></span></p>",
    "unique_key": "Q7149927",
    "question_audio": null,
    "question_video": null,
    "map_id": 36121,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Open angle glaucoma </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Open angle glaucoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a recognized <strong>complication </strong>of prolonged use of <strong>corticosteroid eye drops</strong>. Corticosteroids can cause an <strong>increase in intraocular pressure (IOP) </strong>in some individuals. Over time, this <strong>elevated IOP can damage the optic nerve</strong>, leading to the <strong>development of open-angle glaucoma. </strong>This condition is characterized by the <strong>gradual loss of peripheral vision </strong>and,<strong> </strong>without<strong> </strong>appropriate management, <strong>can progress to blindness. </strong>It is crucial for patients on <strong>long-term corticosteroid eye drop </strong>therapy to have their<strong> IOP monitored </strong>regularly to detect any <strong>increase early and manage </strong>it accordingly<strong> to prevent optic nerve damage and preserve vision</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Posterior subcapsular cataract</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Although <strong>cataract formation, </strong>specifically posterior subcapsular cataracts, can occur with both<strong> systemic and prolonged topical corticosteroid use</strong>, the direct association is<strong> more </strong>commonly emphasized with <strong>systemic therapy</strong>. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Iridocyclitis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is an <strong>inflammatory condition </strong>that<strong> corticosteroid eye drops aim to treat</strong>, rather than a side effect of their use.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Retinoblastoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Retinoblastoma is a type of <strong>eye cancer</strong> unrelated to the use of corticosteroid eye drops. It is <strong>not a complication of corticosteroid therapy</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adverse effects of corticosteroids (</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">with prolonged use<strong> both </strong>as <strong>eye drops as well as systemic use</strong></span><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">G &ndash; G</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">laucoma (on topical use) </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">L &ndash; L</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">imb muscle atrophy </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">U &ndash; U</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">lcer (peptic ulcer) </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C &ndash; C</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ushing syndrome </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">O &ndash; O</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">steoporosis </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C &ndash; C</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ataract (on systemic use) </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">O &ndash; O</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">steonecrosis (avascular necrosis) </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">R &ndash;</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> C/I in <strong>R</strong>enal failure </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">T &ndash;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> C/I in <strong>T</strong>uberculosis (particularly ileo-caecal) </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">I &ndash; I</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">mpair healing. </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C &ndash;</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> C/I in <strong>C</strong>HF </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">O &ndash; O</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">edema </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">I &ndash; I</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">nfections (due to immune-suppressant action) </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D &ndash; D</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">iabetes mellitus </span></span></span></p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S &ndash; S</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">uppression of HPA-axis</span></span></p>",
    "correct_choice_id": 14689,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3689,
    "choices": [
      {
        "id": 14735,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatic dysfunction</span></span></span></p>"
      },
      {
        "id": 14736,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Severe rash</span></span></span></p>"
      },
      {
        "id": 14737,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Agranulocytosis</span></span></span></p>"
      },
      {
        "id": 14738,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anaphylaxis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are potentially serious side effects of thioamide group of anti-thyroid drugs except?</span></span></span></p>",
    "unique_key": "Q3473227",
    "question_audio": null,
    "question_video": null,
    "map_id": 36128,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Anaphylaxis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Thioamides,</strong> such as <strong>methimazole and propylthiouracil, </strong>are <strong>antithyroid drugs</strong> used primarily in the treatment of <strong>hyperthyroidism. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Anaphylaxis is a severe,</strong> potentially<strong> life-threatening allergic reaction </strong>that can occur <strong>rapidly and affect the whole body.&nbsp;</strong>While <strong>allergic</strong> reactions can occur with <strong>any medication</strong>, <strong>anaphylaxis</strong> is <strong>not </strong>a commonly reported <strong>side effect of thioamides. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. </span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatic dysfunction</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a <strong>known serious side effect of thioamides,</strong> particularly<strong> propylthiouracil.</strong> Hepatic dysfunction can range from <strong>mild elevation of liver enzymes to severe liver injury and hepatic failure</strong>.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Severe rash</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Dermatologic reactions, </strong>including severe<strong> rashes</strong>, can occur with <strong>thioamide drugs </strong>and can sometimes be serious enough to<strong> warrant discontinuation of the medication.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Agranulocytosis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A <strong>serious and potentially life-threatening</strong> <strong>decrease</strong> in <strong>white blood cell count, </strong>specifically granulocytes, is a known <strong>side effect</strong> of <strong>thioamides</strong>.<strong> Agranulocytosis </strong>can lead to an<strong> increased risk of infections.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Given the options, the<strong> least likely serious side</strong> effect of thioamide antithyroid drugs is <strong>anaphylaxis</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Anaphylaxis </strong>is<strong> not </strong>a commonly reported <strong>side effect of thioamide antithyroid drugs,</strong> making it the <strong>least likely serious side effect</strong> among the options provided. Common serious side effects include<strong> hepatic dysfunction, severe rashes, and agranulocytosis.</strong></span></span><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\"> </span></span></span></p>",
    "correct_choice_id": 14738,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3943,
    "choices": [
      {
        "id": 15751,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acarbose</span></span></span></p>"
      },
      {
        "id": 15752,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
      },
      {
        "id": 15753,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glipizide</span></span></span></p>"
      },
      {
        "id": 15754,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Table sugar is not used in treating hypoglycemia secondary to?</span></span></span></p>",
    "unique_key": "Q9531872",
    "question_audio": null,
    "question_video": null,
    "map_id": 36126,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Acarbose</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acarbose</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is an <strong>alpha-glucosidase inhibitor</strong> that works by <strong>slowing down</strong> the <strong>digestion of carbohydrates</strong> in the intestine, thereby <strong>blunting the postprandial (after meal)</strong> rise in blood glucose levels. When<strong> hypoglycemia</strong> occurs <strong>secondary to acarbose use,</strong> table <strong>sugar (sucrose) is not</strong> effective for treating the <strong>hypoglycemia</strong> because <strong>acarbose inhibits the enzyme </strong>needed to <strong>break down sucrose</strong> <strong>into glucose</strong>, which can be <strong>absorbed and utilized</strong> by the body. Instead,<strong> glucose (dextrose) tablets or gel </strong>should be used to treat <strong>hypoglycemia </strong>in patients taking<strong> acarbose, as glucose does not </strong>require this <strong>enzymatic breakdown to be absorbed.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Metformin primarily works by<strong> decreasing hepatic glucose production </strong>and <strong>improving insulin sensitivity</strong>. It <strong>does not </strong>directly cause<strong> hypoglycemia</strong> when used alone but can contribute to <strong>low blood sugar levels</strong> if used in combination with other antidiabetic drugs. <strong>Table sugar</strong> can be used to <strong>treat hypoglycemia</strong> <strong>secondary to metformin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Glipizide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Glipizide is a <strong>sulfonylurea</strong> that <strong>stimulates insulin secretion from the pancreatic beta cells</strong>.<strong> Hypoglycemia </strong>caused by<strong> glipizide</strong> can be treated with<strong> table sugar,</strong> as it effectively <strong>raises blood glucose levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Insulin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Insulin</strong> administration can<strong> lead to hypoglycemia</strong> if the dose is <strong>too high </strong>relative to the <strong>patient&#39;s insulin </strong>needs. <strong>Table sugar</strong> is effective in treating <strong>hypoglycemia </strong>secondary to<strong> insulin</strong> use because it quickly <strong>raises blood glucose levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The treatment of <strong>hypoglycemia </strong>in patients taking<strong> acarbose requires glucose (dextrose) </strong>rather than <strong>sucrose (table sugar) </strong>due to <strong>acarbose&#39;s mechanism of action on carbohydrate digestion.</strong></span></span></span></p>",
    "correct_choice_id": 15751,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 3946,
    "choices": [
      {
        "id": 15763,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen receptor antagonist</span></span></span></p>"
      },
      {
        "id": 15764,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">5-&alpha; reductase inhibitor</span></span></span></p>"
      },
      {
        "id": 15765,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">17-&alpha; hydroxylase inhibitor</span></span></span></p>"
      },
      {
        "id": 15766,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aromatase inhibitor</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism of action of finasteride is?</span></span></span></p>",
    "unique_key": "Q3156259",
    "question_audio": null,
    "question_video": null,
    "map_id": 36129,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. 5-&alpha; reductase inhibitor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Finasteride</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> acts as a <strong>5-&alpha; reductase inhibitor</strong>. This class of drugs <strong>inhibits the enzyme 5-&alpha; reductase</strong>, which is responsible for converting <strong>testosterone into dihydrotestosterone (DHT),</strong> a <strong>potent androgen</strong> involved in the development of<strong> benign prostatic</strong> <strong>hyperplasia (BPH) </strong>and <strong>male pattern baldness (androgenetic alopecia)</strong>. By reducing the<strong> production of DHT,</strong> <strong>finasteride helps in</strong> t<strong>reating these conditions.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Example:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Besides <strong>finasteride</strong>, another drug in this class is <strong>dutasteride</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Androgen Receptor Antagonist</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Blocks androgens </strong>like <strong>testosterone and DHT</strong> from<strong> binding to their receptors</strong> in the body.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Example:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Flutamide</strong>, <strong>bicalutamide</strong>, and <strong>enzalutamide</strong> are used primarily in the<strong> treatment of prostate cancer </strong>by<strong> inhibiting</strong> the action of <strong>androgens at their receptor sites.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. 17-&alpha; Hydroxylase Inhibitor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Inhibits</strong> the enzyme<strong> 17-&alpha; hydroxylase,</strong> which is crucial in the <strong>biosynthesis of cortisol and androgens</strong> in the<strong> adrenal</strong> <strong>glands.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Example:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Ketoconazole</strong> (at high doses) can<strong> inhibit adrenal and gonadal steroid synthesis</strong> and is used <strong>off-label </strong>for this purpose, though it is primarily an<strong> antifungal medication.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Aromatase Inhibitor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Blocks</strong> the enzyme <strong>aromatase,</strong> which converts <strong>androgens into estrogens</strong>, thereby reducing <strong>estrogen levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Example:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Anastrozole</strong>, <strong>letrozole</strong>, and <strong>exemestane</strong> are aromatase <strong>inhibitors </strong>used in the treatment of <strong>estrogen receptor-positive</strong> <strong>breast cancer in postmenopausal women.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">DRUGS USED FOR BENIGN PROSTATIC HYPERPLASIA</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamsulosin:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>&nbsp;Alpha 1a-antagonist.</strong> <strong>Decreases</strong> <strong>smooth muscle tone of prostate and bladder neck</strong> which leads to <strong>improved urine flow</strong>, but it will <strong>not lead to reduction in size of prostate.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Finasteride:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> 5-alpha reductase (type II) inhibitor. </strong>Prevents conversion of<strong> testosterone to dihydrotestosterone (DHT)</strong>. DHT causes <strong>growth and differentiation in the prostate</strong>. <strong>Type 2 isoform </strong>of this enzyme is expressed by <strong>stromal cells in the prostate. Reduction </strong>in levels of <strong>DHT prevents further growth </strong>and sometimes reduces the <strong>size of the prostate </strong>as well.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flutamide:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Oral<strong> nonsteroidal antiandrogen </strong>which <strong>inhibits androgen binding to its receptor.</strong> It is used in the treatment of <strong>metastatic prostatic cancer.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tadalafil:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Treatment with <strong>PDE-5 inhibitors</strong> can be considered in patients who have <strong>erectile dysfunction </strong>and <strong>mild or</strong> <strong>moderate symptoms of BPH</strong>. Tadalafil is approved by the <strong>FDA for use in BPH. </strong></span></span><strong> </strong></span></span><strong> </strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 15764,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3956,
    "choices": [
      {
        "id": 15803,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tolvaptan</span></span></span></p>"
      },
      {
        "id": 15804,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin</span></span></span></p>"
      },
      {
        "id": 15805,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">vW factor</span></span></span></p>"
      },
      {
        "id": 15806,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Terlipressin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is used for the treatment of syndrome of inappropriate secretion of ADH (SIADH)? </span></span></span></p>",
    "unique_key": "Q1680595",
    "question_audio": null,
    "question_video": null,
    "map_id": 36133,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Tolvaptan</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>ADH</strong> is secreted in response to <strong>hypovolemia, </strong>in which case<strong> its secretion is appropriate.</strong> However, if <strong>ADH is secreted in high quantities</strong> in presence of <strong>euvolemia or hypervolemia</strong>, it is called<strong> inappropriate secretion (SIADH).</strong> The<strong> resultant water retention</strong> can result in <strong>hyponatremia.</strong> Thus, <strong>SIADH</strong> is characterized by <strong>normovolemic or hypervolemic hyponatremia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Fluid restriction </strong>is treatment of <strong>choice for SIADH.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hypertonic saline (3% NaCl) + loop diuretics (depending upon volume status)</strong> is a treatment of choice for <strong>severe</strong> symptomatic<strong> hyponatremia.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Among drugs, <strong>tolvaptan (oral), conivaptan (IV) </strong>are preferred for <strong>long-term use.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tolvaptan</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a<strong> selective vasopressin V2 receptor antagonist </strong>used in the treatment of the <strong>syndrome of inappropriate secretion of</strong> <strong>antidiuretic hormone (SIADH)</strong>. By <strong>blocking the action </strong>of vasopressin at the<strong> V2 receptors in the renal collecting ducts,</strong> <strong>tolvaptan</strong> <strong>increases water excretion </strong>while sparing<strong> sodium, </strong>leading to an <strong>increase in serum sodium levels in patients with SIADH</strong>, where water r<strong>etention and dilutional hyponatremia </strong>are key problems.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Desmopressin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Desmopressin is a <strong>synthetic analog of antidiuretic hormone (ADH) </strong>used to treat conditions like <strong>central</strong> <strong>diabetes insipidus (where ADH is deficient),</strong> not SIADH, where<strong> ADH secretion is excessive.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. vW factor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Von Willebrand factor (vWF)</strong> concentrates are used in the treatment of<strong> Von Willebrand disease and certain</strong> <strong>types of hemophilia, </strong>not in the management of SIADH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Terlipressin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Terlipressin</strong> is a<strong> synthetic analog of vasopressin </strong>used primarily in the treatment of <strong>esophageal variceal</strong> <strong>bleeding and hepatorenal syndrome,</strong> not SIADH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">For<strong> SIADH</strong>, where<strong> excessive ADH</strong> leads to<strong> water retention and hyponatremia,</strong> <strong>Tolvaptan</strong> is a valuable treatment option due to its <strong>selective action on V2 receptors</strong>, <strong>promoting the correction of sodium levels</strong> while avoiding the <strong>excessive loss of electrolytes.</strong></span></span></span></p>",
    "correct_choice_id": 15803,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3966,
    "choices": [
      {
        "id": 15843,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">1 and 4 correct.</span></span></span></p>"
      },
      {
        "id": 15844,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">2 and 3 correct.</span></span></span></p>"
      },
      {
        "id": 15845,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2, and 3 correct.</span></span></span></p>"
      },
      {
        "id": 15846,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">3 and 4 correct.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The effectiveness of oral contraceptives is reduced by?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Captopril</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Furosemide</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ampicillin</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rifampicin</span></span></span></span></span></li>\r\n</ol>",
    "unique_key": "Q2257481",
    "question_audio": null,
    "question_video": null,
    "map_id": 36131,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. 3 and 4 correct</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> effectiveness of oral contraceptives</strong> can be<strong> reduced</strong> by certain medications that affect their<strong> metabolism or absorption.</strong> Among the options listed:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ampicillin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A <strong>broad-spectrum penicillin antibiotic. </strong>Antibiotics like<strong> ampicillin </strong>can affect the <strong>gut flora</strong>. </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The normal <strong>gastrointestinal flora helps </strong>in the <strong>enterohepatic cycling (and bioavailability) of estrogens</strong>. Antimicrobial drugs like <strong>ampicillin</strong> that <strong>kill these organisms</strong> may <strong>reduce the efficacy of oral contraceptives. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rifampicin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A potent <strong>inducer of hepatic enzymes,</strong> particularly those involved in the <strong>metabolism of drugs. </strong>Rifampicin can significantly <strong>reduce the plasma levels of oral contraceptives </strong>by <strong>increasing their metabolism</strong>, thereby<strong> reducing their</strong> <strong>effectiveness</strong> and<strong> increasing the risk of contraceptive failure</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1. Captopril</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: An <strong>angiotensin-converting enzyme (ACE) inhibitor</strong> used to <strong>treat hypertension and heart failure</strong>. There is <strong>no</strong> evidence to suggest that <strong>captopril significantly affects </strong>the effectiveness of <strong>oral contraceptives.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2. Furosemide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A <strong>loop diureti</strong>c used in the treatment of <strong>edema and hypertension.</strong> Like <strong>captopril, frusemide does not</strong> have a known <strong>interaction</strong> that significantly <strong>reduces the effectiveness of oral contraceptives.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, the correct pairing is</span><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Option C. Ampicillin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> and</span><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> D. Rifampicin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> as<strong> both</strong> can <strong>reduce the effectiveness </strong>of <strong>oral contraceptives</strong> through <strong>different mechanisms</strong>&mdash;<strong>ampicillin</strong> through it<strong>s effect on gut flora </strong>and<strong> rifampicin</strong> through enzyme induction <strong>leading to</strong> <strong>increased metabolism of contraceptives.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Antibiotics</strong> like<strong> ampicillin</strong> and <strong>enzyme inducers </strong>like <strong>rifampicin</strong> can <strong>decrease the effectiveness of oral contraceptives. </strong></span></span></span></p>",
    "correct_choice_id": 15846,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 4106,
    "choices": [
      {
        "id": 16403,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Isophane insulin</span></span></span></p>"
      },
      {
        "id": 16404,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin glargine</span></span></span></p>"
      },
      {
        "id": 16405,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin-zinc suspension</span></span></span></p>"
      },
      {
        "id": 16406,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin degludec</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin having the longest duration of action is?</span></span></span></p>",
    "unique_key": "Q4624156",
    "question_audio": null,
    "question_video": null,
    "map_id": 36107,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Insulin degludec</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Among the options listed, <strong>insulin degludec has the longest duration of action.</strong> It is a<strong> long-acting insulin analog </strong>designed to<strong> help</strong> <strong>control blood sugar levels throughout the day with a single dose</strong>. Its<strong> unique structure</strong> results in a <strong>prolonged duration of action,</strong> which can <strong>exceed 42 hours.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Isophane<strong> insulin (NPH)</strong>: <strong>Intermediate-acting insulin</strong> with an effective duration of <strong>10-20 hours</strong>, making it<strong> shorter in</strong> <strong>duration </strong>compared to <strong>insulin degludec.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option</span></strong> <strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Insulin glargine</strong>: Another<strong> long-acting insulin </strong>with a <strong>duration of approximately 24 hours, </strong>but <strong>still shorter than insulin</strong> <strong>degludec.</strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Insulin-zinc suspension (Lente)</strong>: Consists of <strong>30% amorphous and 70% crystalline insulin</strong>, classified as <strong>intermediate-acting</strong> with a <strong>duration similar to NPH.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin Preparations</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture24.jpg\" style=\"height:424px; width:1000px\" /></span></strong></span></span></p>",
    "correct_choice_id": 16406,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 4112,
    "choices": [
      {
        "id": 16427,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raloxifene</span></span></span></p>"
      },
      {
        "id": 16428,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen</span></span></span></p>"
      },
      {
        "id": 16429,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ospemifene</span></span></span></p>"
      },
      {
        "id": 16430,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clomiphene citrate</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following SERM is approved for treatment of dyspareunia in post-menopausal females?</span></span></span></p>",
    "unique_key": "Q8289459",
    "question_audio": null,
    "question_video": null,
    "map_id": 36109,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Ospemifene</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ospemifene is a selective estrogen receptor modulator (SERM) </strong>that is approved for the <strong>treatment of dyspareunia,</strong> a symptom of <strong>vulvar and vaginal atrophy </strong>due to<strong> menopause</strong>. <strong>Ospemifene</strong> has <strong>estrogenic effects </strong>on the<strong> vaginal epithelium </strong>which help to <strong>relieve</strong> the<strong> symptoms</strong> associated with<strong> vaginal atrophy,</strong> such as <strong>pain during sexual intercourse.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Raloxifene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Raloxifene is a <strong>SERM</strong> that is <strong>used primarily </strong>for the<strong> prevention and treatment of osteoporosis</strong> in <strong>postmenopausal women</strong> and to<strong> reduce the risk of invasive breast cancer</strong> in <strong>postmenopausal women</strong> with <strong>osteoporosis </strong>or at<strong> high</strong> risk for<strong> breast cancer</strong>. It is <strong>not used for dyspareunia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Tamoxifen:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Tamoxifen is used primarily in the <strong>treatment and prevention of breast cancer. </strong>While it has <strong>estrogen-like effects</strong> on certain tissues, it is <strong>not</strong> approved for the t<strong>reatment of dyspareunia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Clomiphene citrate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Clomiphene citrate is used as a <strong>fertility medication to induce ovulation in women </strong>who do not ovulate, including those with <strong>polycystic ovary syndrome (PCOS)</strong>. It is<strong> not </strong>used for the <strong>treatment of dyspareunia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ospemifene</strong> is the <strong>SERM, </strong>approved for the <strong>treatment of dyspareunia in postmenopausal women.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">SELECTIVE ESTROGEN RECEPTOR MODULATORS:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/picture1.jpg\" style=\"height:494px; width:1000px\" /></span></strong></span></span></p>",
    "correct_choice_id": 16429,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 4119,
    "choices": [
      {
        "id": 16455,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin is inappropriate for initial management of type 2 diabetes.</span></span></span></p>"
      },
      {
        "id": 16456,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin decreases hepatic glucose production.</span></span></span></p>"
      },
      {
        "id": 16457,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin undergoes significant metabolism via the cytochrome enzymes.</span></span></span></p>"
      },
      {
        "id": 16458,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Weight gain is a common adverse effect.</span></span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is true about metformin? </span></span></p>",
    "unique_key": "Q1695906",
    "question_audio": null,
    "question_video": null,
    "map_id": 36113,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Metformin decreases hepatic glucose production.</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option B:</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin is an <strong>oral antidiabetic medication </strong>commonly used as the<strong> first-line treatment for type 2 diabetes mellitus</strong>. It primarily works by <strong>decreasing hepatic glucose production,</strong> also known as<strong> gluconeogenesis</strong>, thereby<strong> reducing fasting blood glucose levels.</strong> Additionally, <strong>metformin increases insulin sensitivity</strong> and enhances <strong>peripheral glucose uptake, </strong>especially by <strong>skeletal muscle cells.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Metformin is inappropriate for initial management of type 2 diabetes:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is<strong> false.</strong> Metformin is considered the <strong>first-line therapy</strong> for the management of<strong> type 2 diabetes</strong> in the <strong>absence of contraindications.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Metformin undergoes significant metabolism via the cytochrome enzymes:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is<strong> false.</strong> Metformin is<strong> not</strong> metabolized by the cytochrome P450 enzyme system and is<strong> excreted unchanged in the urine.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Weight gain is a common adverse effect:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is<strong> false. </strong>Unlike some other<strong> diabetes medications, </strong>metformin is <strong>not associated with weight gain</strong> and is often chosen for its<strong> weight-neutral or weight-reducing effect.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metformin </strong>is an effective<strong> first-line treatment for type 2 diabetes</strong> due to its<strong> ability to decrease hepatic glucose production,</strong> <strong>increase</strong> <strong>insulin sensitivity,</strong> and support <strong>peripheral glucose uptake</strong> <strong>without </strong>causing significant<strong> weight gain or undergoing metabolism </strong>by the <strong>liver&#39;s cytochrome P450 system.</strong></span></span> <span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"> </span></span></span></p>",
    "correct_choice_id": 16456,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 4260,
    "choices": [
      {
        "id": 17017,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Does not stimulate insulin release.</span></span></span></p>"
      },
      {
        "id": 17018,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreases hepatic glucose production.</span></span></span></p>"
      },
      {
        "id": 17019,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Can be safely used in patients with renal dysfunction.</span></span></span></p>"
      },
      {
        "id": 17020,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Can be combined with sulfonylureas.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which one of the following statements about metformin is NOT true?</span></span></span></p>",
    "unique_key": "Q2690814",
    "question_audio": null,
    "question_video": null,
    "map_id": 36115,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Can be safely used in patients with renal dysfunction. </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metformin,</strong> a<strong> biguanide </strong>class <strong>antidiabetic medication,</strong> is <strong>contraindicated in patients </strong>with <strong>renal dysfunction.</strong> The drug is primarily <strong>excreted by the kidney</strong>s, and <strong>impaired renal function </strong>can lead to an <strong>increased risk of a severe side effec</strong>t known as<strong> lactic acidosis.</strong> This condition is a <strong>build-up of lactic acid</strong> in the body, which can b<strong>e life-threatening</strong> if not managed promptly. Therefore, <strong>metformin</strong> must be <strong>used with caution </strong>or <strong>avoided in patients with reduced kidney function.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In addition to general restrictions for use of oral hypoglycemic agents, <strong>biguanides</strong> are <strong>contraindicated in hypotensive</strong> <strong>states, cardiovascular, respiratory, hepatic, and renal disease </strong>and in <strong>alcoholics</strong> because of <strong>increased risk of lactic</strong> <strong>acidosis.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>METFORMIN Decrease hepatic glucose </strong>production thereby<strong> reducing insulin resistance. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has <strong>no effect </strong>on <strong>insulin secretion</strong> by<strong> beta cells of pancreas.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin is the <strong>first line drug for type 2 DM </strong>and Can be<strong> combined with </strong>other oral hypoglycemic agents like <strong>sulfonylureas.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin can cause <strong>lactic acidosis</strong> as an adverse effect. It is <strong>contra-indicated </strong>in conditions that <strong>increase the risk </strong>of <strong>lactic acidosis</strong>. These include:</span></span></span>\r\n\t<ul>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiorespiratory insufficiency (Shock, respiratory disease)</span></span></span></strong></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal dysfunction</span></span></span></strong></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liver failure</span></span></span></strong></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elderly</span></span></span></strong></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Does not stimulate insulin release:</strong> This statement is <strong>true.</strong> Metformin works by <strong>improving insulin sensitivity </strong>and <strong>decreasing glucose production in the liver </strong>rather than stimulating insulin release.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Decreases hepatic glucose production:</strong> This statement is <strong>true </strong>and describes one of the primary mechanisms of metformin&#39;s action. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Can be combined with sulfonylureas:</strong> This statement is <strong>true</strong>. <strong>Metformin</strong> is often used in <strong>combination </strong>with <strong>sulfonylureas</strong> to <strong>enhance glucose control in patients with type 2 diabetes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>metformin is a first-line treatment for type 2 diabetes,</strong> its use must be<strong> carefully </strong>considered in patients with<strong> renal dysfunction</strong> due to the<strong> increased risk of lactic acidosis, </strong>a serious and <strong>potentially fatal condition</strong></span></span></span></span></span></p>",
    "correct_choice_id": 17019,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 23768,
    "choices": [
      {
        "id": 95037,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recombinant PTH [rPTH]</span></span></span></p>"
      },
      {
        "id": 95038,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recombinant calcitonin</span></span></span></p>"
      },
      {
        "id": 95039,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recombinant insulin</span></span></span></p>"
      },
      {
        "id": 95040,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Recombinant prolactin</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teriparatide is a drug used in osteoporosis that acts by stimulation of osteoblasts. It is?</span></span></span></p>",
    "unique_key": "Q7532149",
    "question_audio": null,
    "question_video": null,
    "map_id": 36120,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Recombinant PTH [rPTH]</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teriparatide</span></span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is a recombinant preparation of<strong> 1&ndash;34 molecules of amino terminal of human PTH.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It<strong> acts</strong> by <strong>stimulating osteoblasts.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It needs to be given by <strong>subcutaneous injection once daily.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has been found to<strong> increase bone mineral density</strong> in <strong>osteoporotic women.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Its use is recommended for a <strong>period of 2 years.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment with <strong>teriparatide </strong>should be <strong>followed by bisphosphonate therapy.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It <strong>increases the risk of development of osteosarcoma.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Recombinant calcitonin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is<strong> incorrect</strong> as calcitonin is a hormone that primarily <strong>helps regulate calcium levels </strong>by <strong>inhibiting osteoclast activity</strong>, thereby <strong>reducing bone resorption.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Recombinant insulin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect.</strong> Insulin is a hormone related to <strong>glucose metabolism</strong>,<strong> not </strong>directly involved in<strong> bone</strong> <strong>metabolism.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Recombinant prolactin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong>. <strong>Prolactin</strong> is a hormone primarily involved in <strong>lactation</strong> and has <strong>no direct therapeutic</strong> application in <strong>osteoporosis treatment.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Teriparatide</strong>, a <strong>recombinant form of PTH,</strong> is a <strong>unique treatment for osteoporosis </strong>that<strong> stimulates osteoblasts to increase bone</strong> <strong>formation</strong>. Due to its <strong>mode of action and associated risks</strong>, it is used <strong>selectively and typically followed</strong> by treatment with <strong>bisphosphonates </strong>to <strong>consolidate the gains</strong> in <strong>bone density.</strong></span></span></span></span></span></span></p>",
    "correct_choice_id": 95037,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3961,
    "choices": [
      {
        "id": 15823,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Octreotide</span></span></span></p>"
      },
      {
        "id": 15824,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Levo-thyroxine</span></span></span></p>"
      },
      {
        "id": 15825,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cabergoline</span></span></span></p>"
      },
      {
        "id": 15826,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pegvisomant</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only oral drug effective for treatment of condition shown in figure is?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture20.jpg\" style=\"height:383px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q4148344",
    "question_audio": null,
    "question_video": null,
    "map_id": 36135,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Cabergoline</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The figure illustrates the features of<strong> Acromegaly,</strong> which is characterized by the <strong>coarsening of facial features,</strong> <strong>enlargement of the</strong> h<strong>ands and feet, goiter, </strong>and <strong>other systemic </strong>manifestations. Acromegaly is often due to a <strong>growth hormone-secreting pituitary</strong> <strong>adenoma.</strong> The only <strong>oral drug effective</strong> for the treatment of Acromegaly as listed is <strong>Cabergoline,</strong> which is a <strong>dopamine D2 receptor</strong> <strong>agonist</strong>. It<strong> reduces</strong> the release of<strong> growth hormone </strong>and is effective in<strong> controlling the disease.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Octreotide</strong> is <strong>incorrect</strong> because it is an <strong>injectable somatostatin analog </strong>used in the treatment of<strong> Acromegaly. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Levo-thyroxine</strong> is<strong> incorrect </strong>because it is used to <strong>treat hypothyroidism</strong> and has no therapeutic role in the treatment of Acromegaly. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Pegvisomant</strong> is <strong>incorrect </strong>because it is an <strong>injectable growth hormone receptor antagonist</strong> used for <strong>Acromegaly</strong> but is <strong>not</strong> an <strong>oral medication.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DRUGS FOR ACROMEGALY</span></span></strong></span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture21.jpg\" style=\"height:288px; width:1000px\" /></span></span></strong></span></span></strong></span></span></p>",
    "correct_choice_id": 15825,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 4243,
    "choices": [
      {
        "id": 16949,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Afrezza can be used as a replacement for injectable insulin.</span></span></span></p>"
      },
      {
        "id": 16950,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glargine is never mixed with other insulins because of its acidic pH.</span></span></span></p>"
      },
      {
        "id": 16951,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Degludec is a long-acting subcutaneous depot insulin.</span></span></span></p>"
      },
      {
        "id": 16952,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lente is a mixture of 70% crystalline and 30% amorphous insulin.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements about insulin preparations are correct except?</span></span></span></p>",
    "unique_key": "Q5878441",
    "question_audio": null,
    "question_video": null,
    "map_id": 36111,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Afrezza can be used as a replacement for injectable insulin.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Afrezza, a short-acting inhaled insulin, </strong>is primarily utilized to manage<strong> blood glucose levels at meal times</strong> and is characterized by a <strong>rapid onset</strong> and <strong>short duration of action</strong>. While it helps<strong> control postprandial blood sugar spikes,</strong> it<strong> does not</strong> serve as a <strong>standalone</strong> <strong>treatment </strong>and must be used in <strong>conjunction with long-acting injectable insulin</strong> to ensure stable <strong>basal glucose control</strong> throughout the day.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">B.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Glargine is never mixed with other insulins because of its acidic pH:</strong> This statement is <strong>correct.</strong> Insulin glargine has an <strong>acidic pH of about 4,</strong> which can cause <strong>precipitation</strong> when <strong>mixed with other insulins,</strong> hence it should <strong>not be mixed</strong> with them.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Degludec is a long-acting subcutaneous depot insulin:</strong> This statement is<strong> correct. Insulin degludec</strong> provides a<strong> long-acting</strong> <strong>basal insulin effect </strong>due to its<strong> unique formulation t</strong>hat allows it to form a depot after<strong> subcutaneous injection, releasing insulin</strong> <strong>steadily over 24 hours or longer.</strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Lente is a mixture of 70% crystalline and 30% amorphous insulin:</strong> This statement is<strong> correct</strong>. <strong>Lente insulin </strong>is composed of <strong>70% crystalline insulin, </strong>which provides a <strong>longer-acting effect</strong>, and <strong>30% amorphous insulin,</strong> which <strong>acts more quickly, </strong>making it a <strong>mixed intermediate-acting insulin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Afrezza </strong>is <strong>not </strong>a full replacement for <strong>injectable insulin; </strong>it is used to supplement<strong> long-acting insulin </strong>therapies by managing<strong> acute</strong> <strong>meal time blood sugar increases</strong> in patients with diabetes.</span></span></span></span></span></span></p>",
    "correct_choice_id": 16949,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3684,
    "choices": [
      {
        "id": 14715,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bromocriptine- Treatment of precocious puberty</span></span></span></p>"
      },
      {
        "id": 14716,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Octreotide- treatment of diarrhea associated with vasoactive intestinal peptide tumors.</span></span></span></p>"
      },
      {
        "id": 14717,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin- treatment of diabetes insipidus</span></span></span></p>"
      },
      {
        "id": 14718,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leuprolide- treatment of infertility</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following pairs of drugs and its indications is matched incorrectly?</span></span></span></p>",
    "unique_key": "Q4428648",
    "question_audio": null,
    "question_video": null,
    "map_id": 36125,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Bromocriptine- Treatment of precocious puberty</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bromocriptine</strong> is primarily used for the treatment of <strong>hyperprolactinemia, acromegaly, and type 2 diabetes mellitus.</strong> It is<strong> not</strong> indicated for the treatment of<strong> precocious puberty</strong>, where <strong>GnRH analogs like leuprolide </strong>are the <strong>appropriate therapy</strong>. <strong>Bromocriptine&#39;s </strong>mechanism involves<strong> dopamine agonism</strong>, which <strong>inhibits prolactin secretion </strong>but <strong>does no</strong>t play a role in the management of <strong>precocious puberty,</strong> which typically involves <strong>suppressing premature sexual hormone production.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Octreotide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Correctly</strong> matched. Octreotide, an <strong>octapeptide analog of somatostatin, </strong>is effective in reducing the <strong>severe</strong> <strong>secretory diarrhea</strong> associated with conditions like<strong> carcinoid syndrome and vasoactive intestinal peptide tumors (VIPomas).</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Desmopressin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Correctly</strong> matched. Desmopressin is used in the management of<strong> central diabetes insipidus, nocturnal</strong> <strong>enuresis, and von Willebrand&rsquo;s disease.</strong> It acts by <strong>mimicking vasopressin</strong>, thus helping control <strong>urine production </strong>and <strong>improving</strong> <strong>blood clotting factors.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Leuprolide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Correctly matched</strong> when considering its use in <strong>reproductive health.</strong> Leuprolide, a<strong> GnRH analog</strong>, can be administered in a<strong> pulsatile</strong> fashion to treat conditions like <strong>anovulatory infertility</strong>, which relies on <strong>stimulating follicular development and ovulation.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bromocriptine: </span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Used for treatment of <strong>hyperprolactinemia, acromegaly, and type 2 diabetes mellitus.</strong></span></span></span></span></span></span></p>",
    "correct_choice_id": 14715,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3959,
    "choices": [
      {
        "id": 15815,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Canagliflozin</span></span></span></p>"
      },
      {
        "id": 15816,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide</span></span></span></p>"
      },
      {
        "id": 15817,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></span></span></p>"
      },
      {
        "id": 15818,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vildagliptin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Based on the mechanism shown in figure. Drug X is likely to be?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture18.jpg\" style=\"height:153px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q3246588",
    "question_audio": null,
    "question_video": null,
    "map_id": 36134,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Vildagliptin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image describes the <strong>pathway of incretin activation </strong>and its effect on<strong> insulin and glucagon release. Drug X</strong> is illustrated as <strong>inhibiting the enzyme DPP-4 (Dipeptidyl peptidase-4), </strong>which normally <strong>breaks down active GLP-1 (Glucagon-like peptide-1).</strong> By preventing this <strong>breakdown</strong>, Drug <strong>X increases the levels of active GLP-1, </strong>which in turn <strong>increases insulin release and decreases</strong> <strong>glucagon release from the pancreas.</strong> <strong>Vildagliptin </strong>is a known DPP-4 inhibitor, which aligns with the mechanism depicted.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Canagliflozin</strong> is <strong>incorrect</strong> because it is an<strong> SGLT-2 inhibitor,</strong> which promotes <strong>glucosuria</strong> by <strong>preventing glucose reabsorption</strong> <strong>in the renal tubules,</strong> which is unrelated to the DPP-4 inhibition pathway. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is<strong> incorrect</strong> because it is a <strong>GLP-1 analogu</strong>e that mimics the<strong> action of GLP-1 to stimulate insulin release </strong>but does not inhibit DPP-4. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Pramlintide</strong> is<strong> incorrect</strong> because it is an <strong>amylin analogue</strong>, which has a different mechanism of action involving the <strong>modulation of gastric emptying and promotion of satiety;</strong> it does not inhibit DPP-4.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Vildagliptin </strong>is a<strong> DPP-4 inhibitor </strong>that enhances the action of <strong>incretins by preventing the breakdown of active GLP-1,</strong> leading to <strong>increased insulin release and decreased glucagon release</strong>, which helps to <strong>control blood glucose levels </strong>in <strong>diabetes mellitus.</strong></span></span></span></p>",
    "correct_choice_id": 15818,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 3967,
    "choices": [
      {
        "id": 15847,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used as an adjuvant in the treatment of estrogen receptor positive breast cancer.</span></span></span></p>"
      },
      {
        "id": 15848,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It reduces the risk of osteoporosis.</span></span></span></p>"
      },
      {
        "id": 15849,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has a beneficial effect on lipid profile by increasing HDL/LDL cholesterol ratio.</span></span></span></p>"
      },
      {
        "id": 15850,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It reduces the risk of endometrial carcinoma.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements about tamoxifen are true except.</span></span></span></p>",
    "unique_key": "Q1757098",
    "question_audio": null,
    "question_video": null,
    "map_id": 36138,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. It reduces the risk of endometrial carcinoma.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tamoxifen</strong> is a <strong>selective estrogen receptor modulator (SERM) </strong>that has<strong> complex effects</strong> on various tissues. While it acts as an <strong>estrogen receptor antagonist</strong> in<strong> breast tissue,</strong> which is beneficial in the <strong>treatment of estrogen receptor-positive breast cancer,</strong> it paradoxically has an <strong>estrogen agonist effect on the endometrium. </strong>This agonistic action can potentially <strong>increase the risk of</strong> <strong>endometrial carcinoma.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Adjuvant in Estrogen Receptor-Positive Breast Cancer</strong>:<strong> True,</strong> <strong>tamoxifen </strong>is commonly used as an<strong> adjuvant therapy for</strong> <strong>estrogen receptor-positive breast cancer</strong> due to its <strong>antagonistic effects </strong>on the <strong>estrogen receptor in breast tissue. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Risk of Osteoporosis</strong>: <strong>True,</strong> <strong>tamoxifen</strong> has an <strong>estrogen agonistic action</strong> on bone, leading to an <strong>antiresorptive effect</strong> that can <strong>reduce the risk of osteoporosis. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Effect on Lipid Profile</strong>: <strong>True, tamoxifen </strong>is associated with <strong>improvements in lipid profiles</strong>, as it <strong>decreases total and LDL</strong> <strong>cholesterol</strong> <strong>without </strong>significantly affecting <strong>HDL and triglyceride levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen is a <strong>SERM</strong> that has<strong> estrogen agonistic action on bone, blood (lipid profile) and liver </strong>whereas it <strong>acts as</strong> <strong>estrogen receptor antagonist in breast and endometrium.&nbsp; </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is indicated as an<strong> adjuvant in the treatment of estrogen receptor positive breast cancer.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is associated with <strong>reduced risk of cancer in the contralateral breast.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tamoxifen </strong>also <strong>decreases total and LDL cholesterol</strong> without any change in HDL and triglyceride level. It thus has favorable effect on lipid profile by <strong>increasing the HDL/LDL cholesterol ratio</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It also <strong>improves the bone mass due to antiresorptive effect,</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen is <strong>effective orally.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has <strong>biphasic plasma t&frac12; (10 hrs. and 7 days)</strong> and<strong> long duration of action.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hot flushes</strong> and<strong> nausea and vomiting</strong> occur in <strong>25% of patients, </strong>and many other <strong>minor adverse effects</strong> are observed.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tamoxifen</strong> increases the <strong>risk of endometrial carcinoma and thromboembolic events.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It <strong>causes retinal deposits</strong>, <strong>decreased visual acuity and cataracts</strong> in occasional patients&rdquo; </span></span> </span></span></span></li>\r\n</ul>",
    "correct_choice_id": 15850,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3945,
    "choices": [
      {
        "id": 15759,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is an inhalational insulin preparation.</span></span></span></p>"
      },
      {
        "id": 15760,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">By using afreeza, meal-time injectable bolus insulin requirement is not there.</span></span></span></p>"
      },
      {
        "id": 15761,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is given in multiple doses.</span></span></span></p>"
      },
      {
        "id": 15762,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used in combination with short acting insulin.</span></span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All are true regarding insulin &#39;AFREZZA&#39; except?</span></span></p>",
    "unique_key": "Q5034497",
    "question_audio": null,
    "question_video": null,
    "map_id": 36130,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. It is used in combination with short acting insulin.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Afrezza</strong>, being a <strong>rapid-acting insulin itself, </strong>is generally <strong>not</strong> used in <strong>combination with other short-acting insulin preparations.</strong> It may be used along with<strong> long-acting insulin</strong> types in some treatment plans, particularly for individuals with<strong> type 1 diabetes, to ensure</strong> <strong>stable baseline glucose control.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. It is an inhalational insulin preparation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>True. </strong>Afrezza is administered via inhalation, offering an <strong>alternative to injectable</strong> <strong>insulin</strong> forms for <strong>rapid-acting control of blood glucose levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. By using Afrezza, meal-time injectable bolus insulin requirement is not there:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Generally<strong> true</strong>. Afrezza <strong>replaces the need&nbsp;</strong></span></span></span><span style=\"font-family:Calibri,sans-serif; font-size:12pt\">for<strong> meal-time injectable insulin</strong> in many cases. However, some patients might still require an<strong> injectable form</strong> depending on their <strong>specific glucose control</strong> needs and<strong> diabetes management plan.</strong></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. It is given in multiple doses:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> True.</strong> Afrezza is taken at the<strong> start of each meal</strong>, thus it is administered<strong> multiple times</strong> <strong>throughout the day </strong>depending on the<strong> number of meals consumed.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Afrezza</strong> is an<strong> innovative inhalational insulin </strong>that provides<strong> rapid-acting blood glucose control </strong>and can potentially<strong> reduce or eliminate</strong> the need for <strong>meal-time injectable insulin. </strong>It is<strong> not </strong>typically <strong>combined with other short-acting insulins</strong>, making <strong>option D</strong> <strong>the false statement </strong>in the context of this query.</span></span></p>",
    "correct_choice_id": 15762,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3688,
    "choices": [
      {
        "id": 14731,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Saxagliptin</span></span></span></p>"
      },
      {
        "id": 14732,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin</span></span></span></p>"
      },
      {
        "id": 14733,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vildagliptin</span></span></span></p>"
      },
      {
        "id": 14734,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs can be given in renal failure safely?</span></span></span></p>",
    "unique_key": "Q8716558",
    "question_audio": null,
    "question_video": null,
    "map_id": 36127,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Linagliptin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with<strong> type 2 diabetes mellitu</strong>s have dysfunction in <strong>incretin hormones (such as glucagon-like peptide-1 or GLP-1</strong> and <strong>glucose-dependent insulinotropic polypeptide or GIP).</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">By<strong> inhibiting the dipeptidyl peptidase-4 (DPP-4)</strong> enzyme, it is possible to <strong>slow</strong> the <strong>inactivation of GLP-1 and GIP,</strong> promoting<strong> blood glucose level decrease </strong>in a glucose-dependent manner.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Linagliptin</strong> is a <strong>dipeptidyl peptidase-4 inhibitor (DPP IV inhibitor)</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Linagliptin</strong> is approved for the treatment of<strong> type 2 diabetes mellitus</strong> as an<strong> anti-hyperglycemic agent </strong>that can be used as <strong>monotherapy or in combination </strong>with other medications <strong>(metformin, sulphonylurea, pioglitazone, metformin plus</strong> <strong>sulfonylurea or insulin).</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Most gliptins</strong> are avoided in <strong>renal failure except linagliptin.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Saxagliptin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Generally<strong> requires dose adjustments</strong> or is <strong>avoided in patients with renal failure </strong>due to its <strong>renal excretion </strong>and potential for accumulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Vildagliptin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Similar to saxagliptin</strong>, it typically<strong> requires dose modifications i</strong>n patients with<strong> renal impairment</strong> to prevent adverse effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Sitagliptin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Also <strong>primarily eliminated renally,</strong> and thus <strong>needs dose adjustment</strong> in patients with <strong>renal dysfunction to avoid</strong> <strong>potential toxicity.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Linagliptin </strong>is a preferred choice among <strong>dipeptidyl peptidase-4 inhibitors </strong>for patients with<strong> renal failure </strong>due to its <strong>pharmacokinetic</strong> profile that allows <strong>safe use without the need for dosage adjustments </strong>in this population.</span></span></span></span></span></span></p>",
    "correct_choice_id": 14732,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3685,
    "choices": [
      {
        "id": 14719,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></span></span></p>"
      },
      {
        "id": 14720,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
      },
      {
        "id": 14721,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide</span></span></span></p>"
      },
      {
        "id": 14722,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rosiglitazone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old patient with Type 2 diabetes mellitus is being evaluated for potential adjustments to their diabetes management plan. The patient&#39;s current regimen includes metformin and lifestyle modifications. However, recent glycemic control has been suboptimal, and the healthcare provider is considering adding an additional medication to enhance insulin secretion, aiming to achieve better glucose control. Which of the following antidiabetic drugs act by increasing the secretion of insulin, making it a suitable addition to this patient&#39;s diabetes management plan?</span></span></span></p>",
    "unique_key": "Q7165833",
    "question_audio": null,
    "question_video": null,
    "map_id": 36094,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Exenatide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>glucagon-like peptide-1 (GLP-1) receptor agonist.</strong> It works by<strong> increasing insulin secretion </strong>in a glucose-dependent manner, meaning it stimulates <strong>insulin release when blood glucose levels are high.</strong> Additionally, <strong>exenatide slows gastric emptying, suppresses appetite, and inhibits inappropriate post-meal glucagon release,</strong> all of which contribute to<strong> lowering blood glucose</strong> levels. Because of its mechanism of <strong>enhancing insulin secretion</strong> and other <strong>beneficial effects on glucose control, exenatide</strong> is a suitable addition for a patient with<strong> Type 2 diabetes </strong>looking to <strong>improve glycemic control </strong>beyond what has been achieved <strong>with</strong> <strong>metformin and lifestyle modifications.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pramlintide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It is an <strong>amylin analogu</strong>e that <strong>mimics the natural hormone amylin</strong>. Pramlintide <strong>slows gastric emptying,</strong> <strong>reduces postprandial glucagon secretion,</strong> and <strong>promotes satiety</strong>, leading to <strong>decreased caloric intake</strong>. However, it<strong> does not</strong> directly <strong>increase insulin secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a <strong>biguanide,</strong> which is already part of the patient&#39;s regimen. Metformin works mainly by <strong>decreasing</strong> <strong>hepatic glucose production </strong>and improving<strong> insulin sensitivity</strong> but <strong>does not</strong> <strong>increase insulin secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Rosiglitazone</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It belongs to the <strong>thiazolidinedione</strong> class of drugs, which work by<strong> increasing insulin sensitivity</strong> rather than directly<strong> stimulating insulin secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ANTI-DIABETIC DRUGS THAT ACT BY INCREASING THE SECRETION OF INSULIN:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture4.jpg\" style=\"height:744px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 14721,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3636,
    "choices": [
      {
        "id": 14523,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypogonadotropic hypogonadism</span></span></span></p>"
      },
      {
        "id": 14524,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Premature ovarian failure</span></span></span></p>"
      },
      {
        "id": 14525,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperprolactinemia</span></span></span></p>"
      },
      {
        "id": 14526,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polycystic ovarian disease</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old female presented to the hospital with infertility. After thorough examination and relevant investigations, she was prescribed bromocriptine by the gynecologist. Most likely reason of her infertility is.</span></span></span></p>",
    "unique_key": "Q9742322",
    "question_audio": null,
    "question_video": null,
    "map_id": 36097,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Hyperprolactinemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bromocriptine</strong> is a <strong>dopamine agonist</strong> that is primarily used to treat conditions associated with <strong>hyperprolactinemia.</strong> <strong>Hyperprolactinemia</strong> is a condition characterized by an<strong> elevated level of prolactin</strong> in the blood. Prolactin is a hormone <strong>produced by</strong> the<strong> pituitary gland</strong> that, in <strong>high levels</strong>, can <strong>suppress </strong>the production of <strong>gonadotropin-releasing hormone (GnRH), </strong>leading to <strong>reduced</strong> <strong>secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH)</strong>. This suppression can result in <strong>menstrual irregularities</strong> and <strong>anovulation</strong>, making conception difficult. By<strong> lowering prolactin levels</strong>, <strong>bromocriptine</strong> can<strong> restore ovulation and menstrual</strong> <strong>regularity, </strong>thus addressing the<strong> infertility issue</strong> in patients with <strong>hyperprolactinemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hypogonadotropic hypogonadism</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> refers to a condition caused by <strong>insufficient production of gonadotropin-releasing</strong> <strong>hormone (GnRH)</strong> by the <strong>hypothalamus,</strong> leading to<strong> low levels of LH and FSH </strong>and, consequently,<strong> impaired gonadal function.</strong> Treatment typically involves <strong>hormone replacement </strong>rather than <strong>dopamine agonists.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Premature ovarian failure</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is characterized by the<strong> loss of normal ovarian function </strong>before the age of <strong>40</strong>. Women with this condition have <strong>low estrogen levels</strong> and often <strong>elevated gonadotropin levels</strong>. Treatment may include<strong> hormone replacement therapy,</strong> but <strong>not specifically bromocriptine.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Polycystic ovarian disease (PCOD)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, also known as polycystic ovary syndrome (PCOS), is a <strong>hormonal disorder </strong>causing <strong>enlarged ovaries with small cysts on the outer edges</strong>. The<strong> treatment </strong>focuses on managing symptoms and may include<strong> lifestyle</strong> <strong>changes, insulin sensitizers, and fertility treatments</strong>, but<strong> not</strong> typically<strong> bromocriptine unless hyperprolactinemia </strong>is also present.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hyperprolactinemia,</strong> characterized by <strong>elevated levels of prolactin, </strong>can cause <strong>infertility </strong>due to its <strong>suppression </strong>of important reproductive hormones like <strong>GnRH, FSH, and LH</strong>. Bromocriptine helps<strong> restore fertility </strong>by <strong>lowering prolactin levels.</strong></span></span> <span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></p>",
    "correct_choice_id": 14525,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3947,
    "choices": [
      {
        "id": 15767,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2 and 4 are correct.</span></span></span></p>"
      },
      {
        "id": 15768,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2 and 3 are correct.</span></span></span></p>"
      },
      {
        "id": 15769,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only 4 is correct.</span></span></span></p>"
      },
      {
        "id": 15770,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All are correct.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following are adverse effects of SGLT2 inhibitors? </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol start=\"1\" style=\"list-style-type:lower-alpha\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoacidosis </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Urosepsis </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fournier&#39;s gangrene </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Angioedema </span></span></span></li>\r\n</ol>",
    "unique_key": "Q7736644",
    "question_audio": null,
    "question_video": null,
    "map_id": 36095,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. 1, 2 and 3 are correct. </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sodium glucose co-transporter-2 inhibitors (SGLT-2 inhibitors):</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Glucose is freely filtered by the renal glomeruli </strong>and is <strong>reabsorbed in the proximal tubules</strong> by the action of <strong>sodium-glucose transporters (SGLTs). </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sodium-glucose transporter 2<strong> (SGLT2) </strong>accounts for <strong>90% of glucose reabsorption</strong>, and its <strong>inhibition causes glycosuria and</strong> <strong>lowers glucose levels </strong>in patients with <strong>type 2 diabetes. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>SGLT2 inhibitors lower glucose level</strong>s by<strong> changing the renal threshold</strong> and <strong>not by insulin action.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin, </strong>all oral medications, are approved for <strong>clinical use</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Side effects of SGLT2 inhibitors </strong>include <strong>ketoacidosis, urosepsis, Fournier&#39;s gangrene, increased incidence of UTI and</strong> <strong>genital infections.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note - Angioedema (Option d) is not commonly associated with SGLT2 inhibitors</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>SGLT2 inhibitors</strong> are effective for<strong> lowering glucose levels </strong>in patients with <strong>type 2 diabetes,</strong> they can lead to serious side effects such as <strong>ketoacidosis, urosepsis, and Fournier&#39;s gangrene. </strong>It is important for<strong> healthcare </strong>providers to <strong>monitor for signs </strong>of these conditions and for patients to be <strong>aware of their symptoms.</strong></span></span></span></span></span></span></p>",
    "correct_choice_id": 15768,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3963,
    "choices": [
      {
        "id": 15831,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rosiglitazone</span></span></span></p>"
      },
      {
        "id": 15832,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Repaglinide</span></span></span></p>"
      },
      {
        "id": 15833,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide</span></span></p>"
      },
      {
        "id": 15834,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drug&rsquo;s act by increasing the secretion of insulin except? </span></span></span></p>",
    "unique_key": "Q4671072",
    "question_audio": null,
    "question_video": null,
    "map_id": 36099,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Rosiglitazone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Rosiglitazone</strong> is a member of the <strong>thiazolidinediones class of drugs, </strong>which act by<strong> stimulating peroxisome proliferator-activated</strong> <strong>receptor gamma (PPAR-gamma).</strong> This action primarily <strong>increases insulin sensitivity in peripheral tissue </strong>and <strong>does not</strong> directly <strong>increase the secretion of insulin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Repaglinide</strong> is a<strong> meglitinide</strong> which <strong>acts as a potassium ATP (K_ATP) </strong>channel blocker on pancreatic beta cells, directly <strong>stimulating</strong> the<strong> secretion of insulin. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Exenatide</strong> is an <strong>incretin mimetic, </strong>which mimics the action of<strong> incretins like GLP-1 to increase insulin secretion</strong> in response to<strong> high blood glucose levels. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Sitagliptin</strong> is a <strong>dipeptidyl peptidase-4 (DPP-4) inhibitor</strong> that prevents the<strong> breakdown of incretins,</strong> thereby prolonging their action and leading to<strong> increased insulin secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture23.jpg\" style=\"height:642px; width:1000px\" /></p>",
    "correct_choice_id": 15831,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3949,
    "choices": [
      {
        "id": 15775,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Weight loss</span></span></span></p>"
      },
      {
        "id": 15776,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polyuria</span></span></span></p>"
      },
      {
        "id": 15777,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased incidence of urinary tract infections</span></span></span></p>"
      },
      {
        "id": 15778,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the above</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is an adverse effect of dapagliflozin?</span></span></span></p>",
    "unique_key": "Q8634615",
    "question_audio": null,
    "question_video": null,
    "map_id": 36096,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. All the above</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dapagliflozin</strong> is an<strong> SGLT-2 inhibitor</strong> used in the treatment of <strong>type 2 diabetes mellitus.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Glucose </strong>is <strong>freely filtered by the renal glomeruli</strong>. <strong>Sodium-glucose transporter 2 (SGLT2) </strong>accounts for<strong> 90% of glucose</strong> <strong>reabsorption</strong>, and its <strong>inhibition</strong> causes<strong> glycosuria and lowers glucose levels</strong> in patients with <strong>type 2 diabetes. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>SGLT2 inhibitors</strong> <strong>lower glucose levels</strong> by <strong>changing the renal threshold </strong>and not by insulin action.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Due to <strong>increased excretion of glucose in the urine,</strong> dapagliflozin increases the<strong> risk of UTI. </strong>Further, there is<strong> polyuria and</strong> <strong>weight loss with the use of this drug.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other<strong> adverse effects of SGLT2 inhibitors include ketoacidosis, urosepsis, Fournier&#39;s gangrene, and increased incidence of UTI and genital tract infections.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dapagliflozin </strong>and<strong> other SGLT2 inhibitors are effective </strong>in <strong>lowering blood glucose levels in type 2 diabetes patients </strong>but can lead to several adverse effects such as<strong> weight loss, polyuria, and an increased risk of UTIs.</strong> <strong>Patients and healthcare providers</strong> should be aware of these<strong> potential side effects</strong> and<strong> manage them </strong>through <strong>regular monitoring and supportive care.</strong></span></span></span></p>",
    "correct_choice_id": 15778,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3738,
    "choices": [
      {
        "id": 14931,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sucrose</span></span></span></p>"
      },
      {
        "id": 14932,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Galactose </span></span></span></p>"
      },
      {
        "id": 14933,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glucose</span></span></span></p>"
      },
      {
        "id": 14934,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Starch</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient is receiving insulin and acarbose for diabetes mellitus and developed hypoglycemia. Which of the following should be used for treatment of hypoglycemia in this patient?</span></span></span></p>",
    "unique_key": "Q5030756",
    "question_audio": null,
    "question_video": null,
    "map_id": 36098,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Glucose</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the scenario where a patient is <strong>treated with insulin and acarbose and subsequently develops hypoglycemia</strong>, the immediate treatment should involve<strong> administering glucose directly</strong>. Acarbose is an <strong>alpha-glucosidase inhibitor</strong>, which impedes the<strong> breakdown and absorption of complex carbohydrates </strong>in the intestine. Therefore, <strong>treating hypoglycemia with complex carbohydrates like sucrose or polysaccharides (starch) would not </strong>be effective because<strong> acarbose </strong>would<strong> prevent </strong>their <strong>rapid conversion to glucose. </strong>Simple<strong> </strong>carbohydrates like <strong>glucose</strong>, which <strong>do not</strong> require <strong>intestinal digestion</strong>, are the optimal choice as they can be quickly<strong> absorbed into the bloodstream </strong>to <strong>counteract hypoglycemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Sucrose:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Not suitable</strong> for quick correction of<strong> hypoglycemia </strong>in this context because<strong> acarbose inhibits the enzyme </strong>needed to <strong>break down sucrose</strong> into<strong> glucose and fructose, </strong>thereby delaying its <strong>action in raising blood glucose levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Galactose:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While <strong>galactose is a simple sugar</strong>, it is <strong>not </strong>the preferred <strong>treatment for hypoglycemia</strong> as it is <strong>not </strong>as efficiently utilized by the <strong>body as glucose.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Starch:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Starch</strong> is a<strong> complex carbohydrate</strong> that would be<strong> broken down into glucose</strong> much <strong>more slowly</strong>, especially in the presence of <strong>acarbose,</strong> making it <strong>ineffective</strong> for the <strong>immediate treatment of hypoglycemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In cases of<strong> hypoglycemia,</strong> especially in patients using <strong>alpha-glucosidase inhibitors like acarbose</strong>, <strong>direct administration of glucose</strong> is <strong>recommended</strong> as it provides the<strong> fastest and most effective </strong>means of <strong>restoring blood sugar levels</strong> <strong>without </strong>the need for <strong>enzymatic</strong> <strong>digestion.</strong></span></span></span></p>",
    "correct_choice_id": 14933,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3955,
    "choices": [
      {
        "id": 15799,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neutral protamine Hagedorn</span></span></span></p>"
      },
      {
        "id": 15800,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin glulisine</span></span></span></p>"
      },
      {
        "id": 15801,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin glargine</span></span></span></p>"
      },
      {
        "id": 15802,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lente insulin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Longest acting insulin among the following is?</span></span></span></p>",
    "unique_key": "Q8610995",
    "question_audio": null,
    "question_video": null,
    "map_id": 36152,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Insulin glargine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin glargine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is the<strong> longest-acting insulin </strong>among the options listed. It is a <strong>long-acting basal insulin </strong>analog with a <strong>duration of action</strong> that can <strong>last up to 24 hours,</strong> providing a<strong> steady level of insulin </strong>that mimics the <strong>natural basal secretion</strong> by the <strong>pancreas.</strong> <strong>Insulin glargine</strong> is designed to <strong>help control blood sugar levels throughout the day and night, </strong>making it particularly useful for managing<strong> basal insulin requirements in individuals with diabetes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Overall<strong> longest acting insulin is insulin degludec.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Neutral protamine Hagedorn (NPH)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: NPH insulin is an <strong>intermediate-acting insulin </strong>with a <strong>duration of action </strong>that typically ranges from <strong>16 to 24 hours</strong>. While it does provide<strong> longer coverage than short-acting insulins,</strong> it does not last as long as insulin glargine.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Insulin glulisine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Insulin glulisine is a<strong> rapid-acting insulin analog </strong>with a <strong>quick onset of action</strong> (approximately <strong>15 minutes</strong>) and a <strong>shorter duration of action (3 to 5 hours)</strong>, making it <strong>well-suited for controlling blood sugar levels during meals.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Lente insulin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Lente insulin is an <strong>intermediate-acting insulin</strong> with a <strong>duration of action</strong> similar to <strong>NPH insulin.</strong> It is<strong> not</strong> as <strong>long-acting as insulin glargine.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">INSULIN PREPARATIONS</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture15.jpg\" style=\"height:467px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 15801,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3706,
    "choices": [
      {
        "id": 14803,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">GnRH analogue</span></span></span></p>"
      },
      {
        "id": 14804,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Danazol</span></span></span></p>"
      },
      {
        "id": 14805,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyproterone acetate</span></span></span></p>"
      },
      {
        "id": 14806,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medroxyprogesterone acetate</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug of choice for treatment of central precocious puberty in girls is.</span></span></span></p>",
    "unique_key": "Q8861174",
    "question_audio": null,
    "question_video": null,
    "map_id": 36153,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. GnRH analogue</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>GnRH (Gonadotropin-Releasing Hormone) analogues</strong> are the <strong>drug of choice for the treatment of central precocious puberty,</strong> which includes<strong> early puberty onset in girls. </strong>GnRH analogues work by <strong>initially stimulating </strong>and then <strong>downregulating the pituitary gland&#39;s</strong> <strong>release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).</strong> This process leads to a <strong>decrease in sex hormone</strong> <strong>production (estrogen in girls)</strong>, effectively halting the <strong>premature progression of puberty.</strong> The use of<strong> GnRH analogues allows</strong> for the <strong>temporary suspension of sexual maturation, providing time for growth and development </strong>to resume at a more appropriate <strong>chronological age.</strong> </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Please note that<strong> </strong></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>GnRH agonists</strong> are <strong>not effective</strong> as therapy for<strong> peripheral precocious puberty. Androgen antagonists,</strong> <strong>spironolactone, aromatase inhibitors (Anastrozole and Letrozole), ketoconazole, and medroxy-progesterone acetate </strong>are used to<strong> </strong>treat <strong>peripheral precocious puberty.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Danazol</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Danazol is a<strong> synthetic steroid </strong>with <strong>androgenic activity</strong> used to treat <strong>endometriosis and fibrocystic breast disease.</strong> It is <strong>not </strong>the <strong>drug of choice</strong> for treating<strong> precocious puberty.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Cyproterone acetate</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Cyproterone acetate is an <strong>anti-androgen and progestin </strong>medication used for<strong> androgen-dependent</strong> conditions like s<strong>evere acne, excessive hair growth, and androgen-sensitive prostate cancer</strong>. While it can <strong>reduce androgen effects</strong>, it is <strong>not</strong> the primary treatment for<strong> precocious puberty in girls.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Medroxyprogesterone acetate</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Medroxyprogesterone acetate is a <strong>progestin</strong> used as <strong>contraception and in hormone</strong> <strong>therapy </strong>for menopausal symptoms or psychiatric conditions. It is <strong>not </strong>used as the <strong>first-line treatment for precocious puberty.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>GnRH analogues</strong> are the <strong>drug of choice</strong> for<strong> treating central precocious puberty in girls </strong>due to their ability to<strong> control and regulate the</strong> <strong>premature release of sex hormones, </strong>effectively<strong> delaying early puberty.</strong> This treatment is <strong>not</strong> applicable for <strong>peripheral precocious puberty,</strong> which requires different therapeutic approaches like <strong>androgen antagonists or aromatase inhibitors.</strong></span></span></span></p>",
    "correct_choice_id": 14803,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 4241,
    "choices": [
      {
        "id": 16941,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
      },
      {
        "id": 16942,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glimepiride</span></span></span></p>"
      },
      {
        "id": 16943,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pioglitazone</span></span></span></p>"
      },
      {
        "id": 16944,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gliclazide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs used to treat type II diabetes mellitus does not cause weight gain? </span></span></span></p>",
    "unique_key": "Q9446355",
    "question_audio": null,
    "question_video": null,
    "map_id": 36151,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Metformin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metformin </strong>is an <strong>oral antidiabetic medication </strong>that is commonly used as the <strong>first-line treatment for type 2 diabetes mellitus</strong>. One of its benefits, in addition to <strong>lowering blood glucose levels</strong>, is that it <strong>does not cause weight gain</strong> and may even lead to <strong>slight weight</strong> <strong>loss</strong> in some patients. Metformin works by <strong>decreasing hepatic glucose production</strong> and <strong>increasing insulin sensitivity </strong>in<strong> peripheral</strong> <strong>tissues.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Glimepiride:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Glimepiride is a <strong>sulfonylurea</strong>, which works by <strong>increasing insulin secretion</strong> from the <strong>pancreas.</strong> Sulfonylureas can cause<strong> weight gain as a side effect.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Pioglitazone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Pioglitazone is a <strong>thiazolidinedione,</strong> which <strong>improves insulin sensitivity </strong>but is associated with<strong> weight gain,</strong> often due to<strong> fluid retention and fat accumulation.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Gliclazide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Gliclazide is another<strong> sulfonylurea</strong> with a mechanism of action <strong>similar to glimepiride,</strong> and it can also cause <strong>weight gain.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Effect of antidiabetic drugs on weight </span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/picture2.jpg\" style=\"height:153px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 16941,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 4268,
    "choices": [
      {
        "id": 17049,
        "text": "<p><span style=\"font-size:12pt;\">They are active orally.</span></p>"
      },
      {
        "id": 17050,
        "text": "<p><span style=\"font-size:12pt;\">They are estrogen antagonists in all tissues.</span></p>"
      },
      {
        "id": 17051,
        "text": "<p><span style=\"font-size:12pt;\">They have tissue-specific effects.</span></p>"
      },
      {
        "id": 17052,
        "text": "<p><span style=\"font-size:12pt;\">They are more potent than 17-\u03b2-estradiol.</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A second-year medical student is studying the pharmacological properties of estrogens and Selective Estrogen Receptor Modulators (SERMs) to understand their therapeutic applications and mechanisms of action. The student is particularly interested in how SERMs are different compare to natural estrogens, such as 17-\u03b2-estradiol, in their mode of action and effects on various tissues.&nbsp;Compared to 17-\u03b2-estradiol, a natural estrogen, which of the following properties is characteristic of Selective Estrogen Receptor Modulators (SERMs)?\u201d</span></p>",
    "unique_key": "Q5655501",
    "question_audio": null,
    "question_video": null,
    "map_id": 36149,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. They have tissue-specific effects.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Selective Estrogen Receptor Modulators (SERMs),</strong> such as <strong>tamoxifen and raloxifene</strong>, are characterized by their ability to act as <strong>both</strong> <strong>agonists and antagonists of estrogen receptors, </strong>depending on the<strong> tissue type</strong>. This is a key <strong>difference </strong>from <strong>17-\u03b2-estradiol</strong>, which typically <strong>acts as a uniform agonist </strong>across <strong>all estrogen-responsive tissues</strong>. <strong>SERMs</strong> can selectively <strong>mimic</strong> or <strong>block the effects of</strong> <strong>estrogen, </strong>making them <strong>versatilb</strong> in clinical applications, such as in the <strong>treatment of breast cancer </strong>where they <strong>exhibit antagonistic</strong> <strong>properties,</strong> and in <strong>osteoporosis prevention</strong> where they <strong>act as agonists.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. They are active orally: </strong>While many<strong> SERMs</strong> are indeed <strong>orally active,</strong> this is<strong> not </strong>a distinctive feature compared to17-\u03b2-<strong>estradiol,</strong> which can also be <strong>administered orally </strong>in its synthetic forms.</span></p><p><br><span style=\"font-size:12pt;\"><strong>Option B. They are estrogen antagonists in all tissues:</strong> This is <strong>not accurate. SERMs do not </strong>uniformly act as <strong>estrogen antagonists in all tissues</strong>. Instead, their action is <strong>selective like raloxifene is agonistic in some tissues</strong> (like <strong>bones and cardiovascular system</strong>) and <strong>antagonistic</strong> in others (like<strong> breast and uterine tissues</strong>).</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. They are more potent than 17-\u03b2-estradiol:</strong> This is <strong>not </strong>necessarily <strong>true</strong>. The potency of<strong> SERMs compared to 17-\u03b2-estradiol</strong> varies and is<strong> not</strong> the primary <strong>distinguishing facto</strong>r. Their significance lies in their <strong>selective action</strong> <strong>rather than</strong> their<strong> overall potency.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The defining characteristic of<strong> Selective Estrogen Receptor Modulators (SERMs)</strong> is their <strong>tissue-specific effects</strong>, enabling them to <strong>selectively modulate estrogen receptors</strong> in<strong> different tissues</strong>, which <strong>contrasts</strong> with the<strong> uniform agonist activity</strong> of n<strong>atural estrogens</strong> like <strong>17-\u03b2-estradiol </strong>across all <strong>estrogen-responsive tissues.</strong></span></p>",
    "correct_choice_id": 17051,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3664,
    "choices": [
      {
        "id": 14635,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bile acid sequestrant</span></span></span></p>"
      },
      {
        "id": 14636,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">LPL activator</span></span></span></p>"
      },
      {
        "id": 14637,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">CETP inhibitor</span></span></span></p>"
      },
      {
        "id": 14638,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">GLP-1 analogue</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide is a new drug approved for treatment of type 2 diabetes mellitus. What is the mechanism of action of this drug? </span></span></span></p>",
    "unique_key": "Q9968992",
    "question_audio": null,
    "question_video": null,
    "map_id": 36150,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. GLP-1 analogue</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Exenatide </strong>functions as a<strong> GLP-1 (glucagon-like peptide-1) analogue</strong>. This class of <strong>drugs enhances the body&rsquo;s ability </strong>to <strong>regulate blood sugar </strong>by <strong>mimicking the effects </strong>of the naturally occurring <strong>hormone GLP-1</strong>.<strong> Exenatide </strong>stimulates the<strong> pancreas to release insulin more </strong>efficiently when<strong> blood glucose levels are high</strong>. It also<strong> reduces </strong>the rate at which <strong>glucose is absorbed into the bloodstream </strong>by<strong> slowing gastric emptying and suppresses the appetite</strong>, which collectively helps in managing <strong>type 2 diabetes. </strong>It is <strong>administered </strong>via the <strong>subcutaneous route</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Bile acid sequestrant:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect for Exenatide. </strong>Bile acid sequestrants, such as <strong>cholestyramine and colestipol, </strong>are primarily used to manage<strong> dyslipidemia by binding bile acids </strong>in the intestine.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. LPL activator:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>for Exenatide. Drugs that <strong>activate lipoprotein lipase (LPL), </strong>such as <strong>fibrates, </strong>are used to treat <strong>hypertriglyceridemia </strong>by enhancing the breakdown of<strong> triglyceride-rich lipoproteins</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. CETP inhibitor:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>for Exenatide. CETP inhibitors, like <strong>anacetrapib, </strong>are used to <strong>increase high-density lipoprotein (HDL) cholesterol levels </strong>by <strong>inhibiting </strong>the <strong>cholesteryl ester transfer protein</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Exenatide</strong>, as a <strong>GLP-1 analogue</strong>, is effective in treating <strong>type 2 diabetes </strong>by enhancing <strong>insulin secretion </strong>in response to <strong>high blood glucose levels</strong>, <strong>slowing gastric emptying, and reducing appetite</strong>, thus <strong>improving glycemic control</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parenteral Anti-diabetic drugs:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture2.jpg\" style=\"height:230px; width:500px\" /></span></strong></span></span></p>",
    "correct_choice_id": 14638,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 4098,
    "choices": [
      {
        "id": 16371,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduction in number of lymphocytes at the site of inflammation</span></span></span>\u200b\u200b\u200b\u200b</p>"
      },
      {
        "id": 16372,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decrease in production of cytokines.</span></span></span></p>"
      },
      {
        "id": 16373,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of phospholipase enzyme</span></span></span></p>"
      },
      {
        "id": 16374,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the above</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-inflammatory action of cortisol is due to? </span></span></span></p>",
    "unique_key": "Q1825869",
    "question_audio": null,
    "question_video": null,
    "map_id": 36148,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. All the above </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-Inflammatory Effects of corticosteroids</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Inflammation</strong> is characterized by the <strong>extravasation and infiltration of leukocytes into the affected tissue.</strong> <strong>Glucocorticoids</strong> dramatically <strong>reduce</strong> the <strong>manifestations of inflammation. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">After a<strong> single dose of a short-acting glucocorticoid</strong>, the <strong>concentration of neutrophils </strong>in the circulation <strong>increases </strong>while the <strong>lymphocytes (T and B cells), monocytes, eosinophils, and basophils decrease</strong>. The<strong> increase in neutrophils</strong> is due <strong>both to increased influx into the blood from the bone marrow </strong>and to <strong>decreased migration from the blood vessels,</strong> leading to a<strong> reduction in the number of cells </strong>at the site of inflammation. The <strong>reduction in circulating lymphocytes,</strong> <strong>monocytes, eosinophils, and basophils</strong> is primarily the result of their <strong>movement from the vascular bed to lymphoid tissue.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Glucocorticoids</strong> also <strong>inhibit the functions of tissue macrophages </strong>and other <strong>antigen-presenting cells.</strong> The <strong>ability of these</strong> <strong>cells </strong>to respond to<strong> antigens and mitogens is reduced.</strong> The effect on <strong>macrophages </strong>is <strong>particularly marked </strong>and limits their <strong>ability to phagocytose and kill microorganisms </strong>and to <strong>produce tumor necrosis factor &alpha;, interleukin 1,</strong> <strong>metalloproteinases, and plasminogen activator.</strong> Both<strong> macrophages and lymphocytes </strong>produce less<strong> interleukin 12 and</strong> <strong>interferon-&gamma;,</strong> important inducers of<strong> TH1 cell activity, and cellular immunity.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In addition to their effects on <strong>leukocyte function, glucocorticoids influence the inflammatory response</strong> by <strong>inhibiting</strong> <strong>phospholipase A2 </strong>and thus reduce the<strong> synthesis of arachidonic acid, </strong>the<strong> precursor of prostaglandins and leukotrienes,</strong> and of <strong>platelet-activating factor. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Finally, <strong>glucocorticoids reduce </strong>expression of <strong>cyclooxygenase 2 in inflammatory cells, </strong>thus <strong>reducing</strong> the amount of <strong>enzyme</strong> available to<strong> produce prostaglandins.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>anti-inflammatory action of cortisol </strong>and <strong>other glucocorticoids</strong> is <strong>multifactorial,</strong> involving <strong>reduction in immune cell migration</strong> to <strong>inflammation sites,</strong> <strong>decreased production of cytokines, </strong>inhibition of<strong> phospholipase A2 activity</strong>, and <strong>downregulation of COX-2</strong> <strong>expression.</strong></span></span></span></span></span></span></p>",
    "correct_choice_id": 16374,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3965,
    "choices": [
      {
        "id": 15839,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
      },
      {
        "id": 15840,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dapagliflozin</span></span></span></p>"
      },
      {
        "id": 15841,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin</span></span></span></p>"
      },
      {
        "id": 15842,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old female with a history of type 2 diabetes mellitus presents to the clinic with complaints of recurrent urinary tract infections (UTIs) over the past few months. She reports symptoms of urgency, frequency, and dysuria. Her diabetes has been managed with an antidiabetic medication added to her regimen about 6 months ago, around the time the UTIs started becoming more frequent. Her medical history is otherwise unremarkable, and she is not on any other new medications. Which of the following drugs in her treatment regimen is most likely implicated in causing this adverse effect?</span></span></span></p>",
    "unique_key": "Q7541641",
    "question_audio": null,
    "question_video": null,
    "map_id": 36147,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Dapagliflozin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dapagliflozin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a<strong> Sodium-glucose cotransporter 2 (SGLT2) inhibitor</strong> used in the management of<strong> type 2 diabetes mellitus. </strong>SGLT2 <strong>inhibitors</strong> work by<strong> preventing glucose reabsorption in the kidneys,</strong> leading to the <strong>excretion of glucose in the urine</strong>. This mechanism can <strong>increase the risk of urinary tract infections (UTIs) </strong>due to the<strong> higher glucose</strong> content in the<strong> urine,</strong> which can provide a<strong> medium</strong> <strong>for bacterial growth</strong>. The temporal association between the<strong> start of the medication and the onset of recurrent UTIs</strong> in this patient suggests that <strong>dapagliflozin </strong>is the<strong> most</strong> probable <strong>antidiabetic drug </strong>implicated in causing this<strong> adverse effect.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Sitagliptin&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">and <strong>C. Linagliptin</strong>: Both are <strong>Dipeptidyl peptidase-4 (DPP-4) inhibitors. </strong>They work by <strong>increasing incretin levels,</strong> which<strong> inhibit glucagon release and increase insulin secretion</strong>. DPP-4 inhibitors are <strong>not </strong>commonly associated with an <strong>increased risk</strong> <strong>of UTIs.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pramlintide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: An<strong> amylin analogue </strong>used in addition to <strong>insulin therapy in type 1 and type 2 diabetes</strong> to improve <strong>glycemic</strong> control.<strong> Pramlintide </strong>is <strong>not </strong>associated with an<strong> increased risk of UTIs.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dapagliflozin is an SGLT2 inhibitor </strong>that can<strong> increase the risk of urinary tract infections</strong> due to <strong>glucosuria,</strong> which can encourage <strong>bacterial growth </strong>in the urinary tract. <strong>Important points about SGLT2 Inhibitors are -</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These<strong> reduce reabsorption of filtered glucose</strong> and <strong>lowers the renal threshold for glucose</strong>, and thereby <strong>increases urinary</strong> <strong>glucose excretion.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These are <strong>NOT </strong>recommended for patients with <strong>type 1 diabetes mellitus</strong> or for the treatment of <strong>diabetic ketoacidosis.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These should<strong> NOT</strong> be initiated in patients with an&nbsp;<strong>eGFR less than 60 mL/min/1 .73 m<sup>2.</sup></strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Adverse Effects:</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Increases </strong>the risk of <strong>genital mycotic infections.</strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Urinary tract infections.</strong></span></span></span></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypotension.</span></span></span></strong></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">I<strong>mpairment in Renal Function.</strong></span></span></span></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increases in Low-Density Lipoprotein Cholesterol (LDL-C)</span></span></span></strong></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>",
    "correct_choice_id": 15840,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3632,
    "choices": [
      {
        "id": 14507,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corticosteroids</span></span></span></p>"
      },
      {
        "id": 14508,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">DDAVP</span></span></span></p>"
      },
      {
        "id": 14509,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin K</span></span></span></p>"
      },
      {
        "id": 14510,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tranexamic acid</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old male presents to the clinic with a history of mild hemophilia A. He reports experiencing prolonged bleeding after minor injuries and is seeking options for management. Which of the following drug can be used in the treatment of mild hemophilia?&nbsp; </span></span></span></p>",
    "unique_key": "Q2318300",
    "question_audio": null,
    "question_video": null,
    "map_id": 36140,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. DDAVP</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>DDAVP</strong> is other name of <strong>desmopressin</strong>. </span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is the <strong>drug of choice </strong>for the treatment of <strong>mild hemophilia A.</strong> Desmopressin is a <strong>synthetic</strong> <strong>analog </strong>of the <strong>natural antidiuretic hormone vasopressin. </strong>It works by stimulating <strong>V2 receptors</strong> that result in the <strong>release of von</strong> <strong>Willebrand factor and factor VIII from endothelial cells</strong>. This<strong> increase in factor VIII levels </strong>can<strong> temporarily correct </strong>the <strong>clotting defect</strong> in patients with <strong>mild hemophilia A,</strong> thereby <strong>reducing the risk of bleeding </strong>during <strong>surgeries or after injuries</strong>. <strong>DDAVP</strong> can be administered <strong>intravenously, subcutaneously, or as a nasal spray, </strong>making it a<strong> versatile</strong> and effective option for<strong> managing mild</strong> <strong>hemophilia A.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin K</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is essential for the <strong>synthesis </strong>of certain <strong>clotting factors (II, VII, IX, and X) </strong>but is<strong> not </strong>effective in <strong>treating hemophilia, </strong>which is caused by a<strong> deficiency or dysfunction of factor VIII (in hemophilia A) or factor IX (in hemophilia B),</strong> <strong>not by a vitamin K deficiency.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Corticosteroids</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> are <strong>not used</strong> in the treatment of <strong>hemophilia. </strong>They are primarily used to<strong> treat inflammation and</strong> <strong>autoimmune conditions</strong> and have<strong> no role </strong>in <strong>increasing clotting factors in hemophilia patients.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Tranexamic acid</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is an <strong>antifibrinolytic agent</strong> that prevents the <strong>breakdown of blood clots. </strong>While it can be useful in managing <strong>bleeding in hemophilia patients</strong>, particularly in <strong>mucosal bleeding or during dental procedures,</strong> it <strong>does not </strong>address the underlying<strong> clotting factor deficiency</strong> and is typically used as an <strong>adjunct to factor replacement therapy</strong> rather than as a <strong>primary</strong> treatment.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>aim </strong>is to understand the <strong>treatment modalities </strong>available for managing <strong>mild hemophilia A,</strong> with a focus on the use of <strong>DDAVP</strong> <strong>(Desmopressin)</strong> as an effective option for <strong>increasing the levels of factor VIII,</strong> thereby<strong> temporarily </strong>correcting the <strong>clotting defect</strong>. </span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can result in <strong>release of factor VIII and vWF from the endothelium.</strong> </span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> </span></span></span></span></span></span></p>",
    "correct_choice_id": 14508,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3721,
    "choices": [
      {
        "id": 14863,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cimetidine</span></span></span></p>"
      },
      {
        "id": 14864,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methysergide</span></span></span></p>"
      },
      {
        "id": 14865,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bromocriptine</span></span></span></p>"
      },
      {
        "id": 14866,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ondansetron</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is used in the treatment of hyperprolactinemia? </span></span></span></p>",
    "unique_key": "Q9732194",
    "question_audio": null,
    "question_video": null,
    "map_id": 36139,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Bromocriptine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bromocriptine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>dopamine agonist </strong>that is used in the treatment of <strong>hyperprolactinemia</strong>. Hyperprolactinemia is a condition characterized by <strong>elevated levels of prolactin </strong>in the blood, which can cause various symptoms, including <strong>amenorrhea, galactorrhea,</strong> <strong>infertility, and hypogonadism</strong>. Bromocriptine works by<strong> activating dopamine D2 receptors</strong>, which <strong>inhibits the secretion of prolactin</strong> from the<strong> pituitary gland.</strong> It is an effective treatment for <strong>lowering prolactin levels </strong>and <strong>alleviating the symptoms </strong>associated with <strong>hyperprolactinemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Cimetidine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Cimetidine is a <strong>histamine H2 receptor antagonist </strong>used primarily to treat <strong>peptic ulcer disease and</strong> g<strong>astroesophageal reflux disease (GERD)</strong>. It is <strong>not </strong>used in the treatment of <strong>hyperprolactinemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Methysergide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Methysergide</strong> is a medication used to <strong>prevent migraine headache.</strong> It is not used for the treatment of hyperprolactinemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ondansetron</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Ondansetron is a <strong>serotonin 5-HT3 receptor antagonist </strong>used primarily to <strong>prevent nausea and vomiting</strong> associated with <strong>chemotherapy, radiation therapy, and surgery. </strong>It is <strong>not </strong>used in the treatment of <strong>hyperprolactinemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uses of Dopamine Agonists</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture7.jpg\" style=\"height:396px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 14865,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3954,
    "choices": [
      {
        "id": 15795,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glibenclamide&mdash;Na K ATPase blocker</span></span></span></p>"
      },
      {
        "id": 15796,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Biguanides&mdash;AMP kinase activation</span></span></span></p>"
      },
      {
        "id": 15797,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vildagliptin&mdash;SGLT2 inhibitor</span></span></span></p>"
      },
      {
        "id": 15798,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Voglibose&mdash;DPP4 inhibitor</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following pairs of antidiabetic drug and its mechanism of action is correct?</span></span></span></p>",
    "unique_key": "Q9391431",
    "question_audio": null,
    "question_video": null,
    "map_id": 36142,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Biguanides&mdash;AMP kinase activation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Biguanides, specifically metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, the most commonly used drug in this class, work by <strong>activating AMP-activated protein kinase (AMPK)</strong>. This activation leads to a<strong> decrease in hepatic glucose production (gluconeogenesis) </strong>and an <strong>increase in insulin sensitivity,</strong> which enhances <strong>peripheral glucose uptake. </strong>This mechanism contributes to the<strong> lowering of blood glucose levels without </strong>stimulating <strong>insulin secretion</strong>, making it a foundational treatment for<strong> type 2 diabetes mellitus.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Glibenclamide&mdash;Na K ATPase blocker</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This statement is<strong> incorrect. Glibenclamide</strong> (also known as<strong> glyburide </strong>in some regions) is a <strong>sulfonylurea</strong>, which acts as a <strong>K_ATP channel blocker</strong> on <strong>pancreatic beta cells,</strong> thereby <strong>stimulating insulin secretion</strong>. It <strong>does not block Na K ATPase.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Vildagliptin&mdash;SGLT2 inhibitor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This statement is <strong>incorrect.</strong> Vildagliptin is a <strong>DPP-4 inhibitor</strong>, not an SGLT2 inhibitor. It works by <strong>preventing the breakdown of incretin hormones</strong>, which <strong>increases insulin release and decreases glucagon levels </strong>in a glucose-dependent manner.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Voglibose&mdash;DPP4 inhibitor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This statement is<strong> incorrect</strong>. Voglibose is an <strong>alpha-glucosidase inhibitor</strong>, not a DPP-4 inhibitor. It works by <strong>delaying the digestion of carbohydrates</strong>, thereby <strong>blunting postprandial blood glucose spikes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Biguanides </strong>like<strong> metformin activate AMPK, l</strong>eading to <strong>decreased hepatic glucose production and increased insulin sensitivity without directly stimulating insulin secretion</strong>. This<strong> mechanism</strong> is fundamental in the management of<strong> type 2 diabetes, </strong>making it a cornerstone of therapy.</span></span></p>",
    "correct_choice_id": 15796,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3958,
    "choices": [
      {
        "id": 15811,
        "text": "<p>\u200b\u200b\u200b\u200b\u200b\u200b<span style=\"font-size:12pt;\">Pramlintide</span></p>"
      },
      {
        "id": 15812,
        "text": "<p><span style=\"font-size:12pt;\">Canagliflozin</span></p>"
      },
      {
        "id": 15813,
        "text": "<p><span style=\"font-size:12pt;\">Exenatide</span></p>"
      },
      {
        "id": 15814,
        "text": "<p><span style=\"font-size:12pt;\">Vildagliptin</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Drug Z shown in figure is likely to be?</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture17.jpg\" alt=\"\" width=\"600\" height=\"358\"></span></p>",
    "unique_key": "Q1281177",
    "question_audio": null,
    "question_video": null,
    "map_id": 36143,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B. Canagliflozin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The diagram </span><span style=\"font-size:12.0pt;\">illustrates normal physiology of urine formation, </span><span style=\"font-size:12pt;\"><strong>renal glucose reabsorption process, highlighting SGLT2 and SGLT1 co-transporters. </strong></span><span style=\"font-size:12.0pt;\">Normally SGLT 2 cotransporter is present in proximal tubule, so no glucose is seen in urine.</span><span style=\"font-size:12pt;\"><strong> Canagliflozin</strong> is a <strong>Sodium-glucose co-transporter-2 (SGLT-2) inhibitor.</strong> It works by<strong> inhibiting the SGLT2 transporter,</strong> which is responsible for <strong>90% of</strong> <strong>glucose reabsorption in the kidney, </strong>as shown by the marked location in the<strong> proximal tubule</strong> in the figure. By <strong>inhibiting</strong> this <strong>transporter, Canagliflozin </strong>causes<strong> increased excretion of glucose in the urine (glucosuria), </strong>thus <strong>lowering blood glucose levels</strong> in patients with <strong>type 2 diabetes.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p><br><span style=\"font-size:12pt;\"><strong>Option A.</strong> <strong>Pramlintide</strong> is <strong>incorrect</strong> because it is an<strong> amylin analogue</strong>, <strong>not an SGLT2 inhibitor.</strong> It is used in the treatment of <strong>type 1 and</strong> <strong>type 2 diabetes mellitus </strong>to complement insulin therapy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong> <strong>Exenatide</strong> is<strong> incorrect </strong>because it is a<strong> GLP-1 (glucagon-like peptide-1) analogue</strong>, which stimulates <strong>insulin release</strong> and is not involved in the renal reabsorption of glucose.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong> <strong>Vildagliptin</strong> is<strong> incorrect </strong>because it is a<strong> DPP-4 (Dipeptidyl peptidase-4) inhibitor </strong>that prolongs the action of <strong>endogenous</strong> <strong>GLP-1,</strong> thereby <strong>increasing insulin secretion,</strong> but <strong>does not</strong> directly cause<strong> glucosuria as SGLT2 inhibitors do.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Sodium glucose co-transporter-2 inhibitors (SGLT-2 inhibitors):</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Glucose </strong>is<strong> freely filtered </strong>by the <strong>renal glomeruli </strong>and is <strong>reabsorbed in the proximal tubules</strong> by the action of <strong>sodium-glucose transporters (SGLTs).</strong></span></li><li><span style=\"font-size:12pt;\">Sodium-glucose transporter 2 (SGLT2) accounts for <strong>90% of glucose reabsorption</strong>, and its <strong>inhibition causes glycosuria and</strong> <strong>lowers glucose levels in patients with type 2 diabetes.</strong></span></li><li><span style=\"font-size:12pt;\">SGLT2 inhibitors <strong>lower glucose levels</strong> by changing the <strong>renal threshold</strong> and not by insulin action.</span></li><li><span style=\"font-size:12pt;\">The <strong>SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin</strong>, all oral medications, are approved for clinical use.</span></li><li><span style=\"font-size:12pt;\"><strong>Side effects</strong> of SGLT2 <strong>inhibitors include ketoacidosis, urosepsis, Fournier's gangrene, increased incidence of UTI and genital infections.</strong></span></li></ul>",
    "correct_choice_id": 15812,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 3960,
    "choices": [
      {
        "id": 15819,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Monophasic combined OCPs</span></span></span></p>"
      },
      {
        "id": 15820,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Biphasic combined OCPs</span></span></span></p>"
      },
      {
        "id": 15821,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triphasic combined OCPs</span></span></span></p>"
      },
      {
        "id": 15822,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Emergency pills</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The oral contraceptives shown in the figure are.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture19.jpg\" style=\"height:194px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q6639365",
    "question_audio": null,
    "question_video": null,
    "map_id": 36144,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Monophasic combined OCPs</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Figure shows <strong>monophasic oral contraceptive pills. 28 tablets </strong>with<strong> 21 one colored (</strong>with same hormone content of <strong>Estrogen and Progesterone)</strong> and <strong>7 different coloreds</strong> (contains only <strong>iron without Estrogen and Progesterone</strong>). </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note: Please do not mark the answer as biphasic pills by seeing two colors in the drug strip.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">B. Biphasic pills will have three colors.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The <strong>first 10 tablets </strong>with <strong>less content of E+P, </strong>the next <strong>11 tablets of different color</strong> containing <strong>higher amounts of hormones </strong>and last<strong> 7 tablets of different color</strong> that contain only <strong>iron.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C. Triphasic pills will have four colors.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> First 6 tablets, 6-10 tablets, 11-21 tablets and last 7 tablets </strong>of <strong>different color.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp; <strong>Emergency pills</strong> are <strong>incorrect</strong> because<strong> emergency contraception</strong> is<strong> not</strong> presented in a<strong> 28-day </strong>format but rather as a<strong> one-time dose </strong>or a <strong>short series of pills</strong> intended for <strong>immediate use after unprotected sex.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<br />\r\n<strong>Monophasic combined OCPs</strong> consist of <strong>21 active pills</strong> with a consistent dose of <strong>estrogen and progesterone</strong>, followed by <strong>7 non-hormonal (iron) pills,</strong> and are represented in a pack with <strong>two colors&mdash;21 of one color</strong> and <strong>7 of another, </strong>not to be confused with <strong>biphasic or triphasic pills </strong>which have<strong> varying hormone dosages and more color variation.</strong></span></span></span></p>",
    "correct_choice_id": 15819,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 4249,
    "choices": [
      {
        "id": 16973,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Previous hysterectomy</span></span></span></p>"
      },
      {
        "id": 16974,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recurrent vaginitis</span></span></span></p>"
      },
      {
        "id": 16975,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Strong family history of breast cancer</span></span></span></p>"
      },
      {
        "id": 16976,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Troublesome hot flushes</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">52-year-old postmenopausal patient has evidence of low bone mineral density. She and her physician are considering therapy with raloxifene or a combination of conjugated estrogens and medroxyprogesterone acetate. Which of the following patient characteristics is most likely to lead them to select raloxifene? </span></span></span></p>",
    "unique_key": "Q6466167",
    "question_audio": null,
    "question_video": null,
    "map_id": 36145,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Strong family history of breast cancer</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Raloxifene</strong> is a<strong> selective estrogen receptor modulator (SERM) </strong>that has<strong> estrogenic effects on bone</strong> and <strong>lipid metabolism </strong>but <strong>acts as</strong> an<strong> estrogen antagonist on breast and endometrial tissues</strong>. Given its <strong>antagonistic effects on breast tissue,</strong> raloxifene can decrease the risk of <strong>breast cancer</strong>, which makes it a particularly <strong>suitable choice for a patient with a strong family history of breast cancer. </strong>This <strong>contrasts </strong>with<strong> hormone replacement therapy (HRT) </strong>using a combination of <strong>estrogen and progesterone,</strong> which has been associated with an<strong> increased risk of breast cancer.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Previous hysterectomy:</strong> Previous hysterectomy is a<strong> better option </strong>fo<strong>r those drugs</strong> which<strong> increase risk of endometrial</strong> <strong>carcinoma,</strong> as there is <strong>no endometrium, </strong>so<strong> no risk.</strong> As <strong>raloxifene does not increase the risk</strong> (rather it<strong> decreases the risk</strong>) of <strong>endometrial carcinoma, </strong>this characteristic<strong> would not </strong>influence the <strong>choice towards raloxifene. </strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">B.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Recurrent vaginitis:</strong> <strong>Patients suffering</strong> from <strong>recurrent vaginitis </strong>might <strong>benefit more from estrogen therapy, </strong>which can help maintain <strong>vaginal health and pH balance</strong>, rather than raloxifene.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Troublesome hot flushes:</strong> Raloxifene is <strong>not effective for the treatment of hot flushes</strong> and might actually<strong> exacerbate them.</strong> In this case, <strong>HRT would be more appropriate</strong> to <strong>alleviate menopausal symptoms</strong> such as <strong>hot flushes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hormone replacement therapy (Combination of estrogen and progesterone) </strong>increases the risk of <strong>breast cancer </strong>whereas <strong>raloxifene</strong> has<strong> protective effective on breast cancer.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Actions of Raloxifene:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a <strong>selective estrogen receptor modulator.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It acts like an <strong>estrogen agonist in bone</strong> and<strong> decreases bone resorption</strong>. Thus, it is used for treatment of <strong>osteoporosis.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It<strong> increases HDL/LDL cholesterol ratio</strong> and thus has a favorable effect on<strong> lipid profile.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It<strong> acts as ER antagonist </strong>on<strong> breast and endometrial tissue </strong>and thus can<strong> decrease the risk of breast cancer</strong> as well as <strong>endometrial cancer.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It<strong> increases </strong>the formation of<strong> clotting factors</strong> and thus the risk of<strong> thromboembolism is increased</strong> with the<strong> use of</strong> <strong>raloxifene</strong>.</span></span></span></span></span></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 16975,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3642,
    "choices": [
      {
        "id": 14547,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quick relief of symptoms</span></span></span></p>"
      },
      {
        "id": 14548,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">To increase the metabolism of thyroxine</span></span></span></p>"
      },
      {
        "id": 14549,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">To blockade the thyroxine receptors</span></span></span></p>"
      },
      {
        "id": 14550,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">To decrease the synthesis of thyroxine</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyroid storm is medical emergency in which there is excessive secretion of thyroid hormones. Beta blockers like propranolol are commonly used in a patient of thyroid storm. What is the most important role of beta blockers in these patients?</span></span></span>\u200b\u200b\u200b\u200b\u200b\u200b</p>",
    "unique_key": "Q8294768",
    "question_audio": null,
    "question_video": null,
    "map_id": 36146,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Quick relief of symptoms </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyroid storm (Thyrotoxic Crisis)</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is<strong> an emergency</strong> due to <strong>decompensated hyperthyroidism.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment includes:</span></span></span></li>\r\n</ul>\r\n\r\n<ol>\r\n\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-selective &beta;-blocker </span></span></span></strong>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is the<strong> mos</strong>t valuable measure in <strong>thyroid storm. </strong>In thyroid storm most of the symptoms are <strong>because of</strong> <strong>adrenergic overactivity. </strong>This occurs due to<strong> increased tissue sensitivity to catecholamines </strong>(resulting from upregulation of &beta;-receptors) in <strong>hyperthyroidism. </strong>So, quick relief can be obtained by <strong>blocking &beta;-receptors.</strong> <strong>Propranolol is a lifesaving drug in thyroid storm. </strong>It <strong>not only reverses the symptom</strong>s but also <strong>decrease the</strong> <strong>peripheral conversion of T4 to T3.</strong></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Calcium channel blocker</strong>s like <strong>diltiazem</strong> may be added if <strong>tachycardia</strong> is <strong>not </strong>controlled by <strong>propranolol alone.</strong></span></span></span></li>\r\n\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propylthiouracil</span></span></span></strong>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is the <strong>antithyroid drug of choice for thyroid storm</strong> because it <strong>reduces hormone synthesis</strong> as well as <strong>peripheral conversion of T4 to T3.</strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note: <strong>Propylthiouraci</strong>l is the<strong> DOC </strong>amongst<strong> antithyroid drugs</strong>, but the<strong> DOC for thyroid storm is &beta;-blockers.</strong></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corticosteroid (Hydrocortisone) </span></span></span></strong>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It<strong> inhibits </strong>both <strong>release of thyroid hormone from the gland and peripheral conversion of T4 to T3.</strong></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. To increase the metabolism of thyroxine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong> because<strong> beta blockers do not increase the metabolism of thyroxine but reduce the conversion of T4 to T3.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. To blockade the thyroxine receptors:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> because <strong>beta blockers do not</strong> affect <strong>thyroxine receptors;</strong> they <strong>block &beta;-adrenergic receptors.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. To decrease the synthesis of thyroxine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>as beta blockers<strong> do not</strong> directly <strong>decrease the synthesis of thyroid</strong> <strong>hormones</strong>; this effect is<strong> mediated by drugs</strong> like <strong>propylthiouracil.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Additional Treatment Insights:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Calcium channel blockers</strong> like<strong> diltiazem </strong>may be used if<strong> tachycardia persists despite beta-blocker therapy</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Propylthiouracil </strong>is the preferred<strong> antithyroid drug </strong>as it <strong>reduces hormone synthesis</strong> and<strong> peripheral conversion of T4 to</strong> <strong>T3.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Corticosteroids</strong> like <strong>hydrocortisone</strong> are administered to<strong> inhibit both the release of thyroid hormone from the gland and</strong> <strong>the peripheral conversion of T4 to T3.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a <strong>thyroid storm, beta blockers</strong> such as<strong> propranolol</strong> are essential for quickly <strong>alleviating symptoms</strong> through<strong> &beta;-receptor blockade </strong>and<strong> reducing the peripheral conversion of T4 to T3</strong>, thereby <strong>mitigating </strong>the effects of <strong>excess thyroid hormones.</strong></span></span></span></span></span></p>",
    "correct_choice_id": 14547,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3953,
    "choices": [
      {
        "id": 15791,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta galactosidase inhibitor</span></span></span></p>"
      },
      {
        "id": 15792,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta lactase inhibitor</span></span></span></p>"
      },
      {
        "id": 15793,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha glucosidase inhibitor</span></span></span></p>"
      },
      {
        "id": 15794,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta glucosidase inhibitor</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism of action of Voglibose is?</span></span></span></p>",
    "unique_key": "Q1440014",
    "question_audio": null,
    "question_video": null,
    "map_id": 36141,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Alpha glucosidase inhibitor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Voglibose</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> acts as an <strong>alpha-glucosidase inhibitor</strong>. This class of medications works by <strong>inhibiting alpha-glucosidase enzymes</strong> in the <strong>small intestine </strong>responsible for<strong> breaking down carbohydrates into glucose.</strong> By inhibiting these enzymes, v<strong>oglibose slows down the</strong> <strong>digestion and absorption of carbohydrates,</strong> leading to a <strong>more gradual rise in blood glucose levels post-meal</strong>. This mechanism makes <strong>alpha-glucosidase inhibitors effective</strong> in managing<strong> postprandial hyperglycemia </strong>in people with<strong> type 2 diabetes mellitus.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Beta galactosidase inhibitor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: There is<strong> no therapeutic class</strong> specifically targeting<strong> beta galactosidase for diabetes</strong> management. Beta galactosidase is involved in the<strong> metabolism of lactose into glucose and galactose.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Beta lactase inhibitor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The term &quot;beta lactase&quot; is <strong>incorrect as lactase (not &quot;beta lactase&quot;) i</strong>s the enzyme that b<strong>reaks down</strong> <strong>lactose into glucose and galactose,</strong> and there are <strong>no diabetes medications targeting this enzyme.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Beta glucosidase inhibitor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Beta glucosidase plays a role in <strong>carbohydrate digestion</strong>, but <strong>inhibiting this enzyme</strong> is <strong>not a</strong> mechanism utilized by<strong> voglibose or other antidiabetic drugs.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></span></strong></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\">&nbsp;<br />\r\n<span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Voglibose</strong> is an <strong>alpha-glucosidase inhibitor </strong>used to manage <strong>postprandial blood glucose levels in patients with type 2 diabetes</strong>. Its primary action is to <strong>slow carbohydrate digestion and absorption, </strong>which helps in<strong> controlling spikes in blood sugar levels after meals.</strong></span></span></span></p>",
    "correct_choice_id": 15793,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3647,
    "choices": [
      {
        "id": 14567,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Terlipressin is preferred over desmopressin for treatment of bleeding esophageal varices.</span></span></span></p>"
      },
      {
        "id": 14568,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin is not useful for treatment of nephrogenic diabetes insipidus.</span></span></span></p>"
      },
      {
        "id": 14569,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiloride is used for treatment of lithium induced diabetes insipidus.</span></span></span></p>"
      },
      {
        "id": 14570,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin can be used for treatment of both pituitary and renal diabetes insipidus.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements are true except.</span></span></span></p>",
    "unique_key": "Q4647351",
    "question_audio": null,
    "question_video": null,
    "map_id": 36155,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Desmopressin can be used for treatment of both pituitary and renal diabetes insipidus.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is <strong>selective agonist of V2 receptors </strong>of vasopressin.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Diabetes insipidus (DI) of pituitary origin (neurogenic) </strong>is the most important <strong>indication for desmopressin.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is <strong>ineffective in renal (nephrogenic) Dl </strong>since the<strong> kidney is unresponsive to ADH.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, <strong>desmopressin is the drug of choice for central diabetes insipidus </strong>and <strong>not </strong>much effective <strong>against nephrogenic diabetes insipidus.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be used by<strong> intranasal route and oral routes</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical Indications: </span></span></span>\r\n\t<ul>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Central diabetes insipidus.</span></span></span></strong></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nocturnal enuresis in children.</span></span></span></strong></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemophilia.</span></span></span></strong></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">von Willebrand&rsquo;s Disease.</span></span></span></strong></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In case of esophageal variceal bleeding:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Terlipressin </strong>&iexcl;s a <strong>synthetic analogue of vasopressin </strong>with <strong>V1 agonistic action</strong>. It has <strong>longer activity and fewer side effects.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It <strong>reduces</strong> <strong>portal pressure </strong>and can be used in<strong> esophageal variceal bleeding.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Desmopressin </strong>has shown<strong> no clinical benefits </strong>&iexcl;n the setting of <strong>variceal bleeding.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In case of lithium induced diabetes insipidus</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiloride </strong>is the <strong>drug of choice</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It <strong>blocks </strong>entry of<strong> Li+ through Na+ channels in the CD cells </strong>and mitigates<strong> diabetes insipidus </strong>induced by<strong> lithium</strong>. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Terlipressin is preferred over desmopressin for treatment of bleeding esophageal varices:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>True.</strong> Terlipressin, a <strong>synthetic</strong> <strong>analogue of vasopressin </strong>with <strong>V1 agonistic</strong> action, <strong>reduces portal pressure</strong> and is preferred in the<strong> treatment of esophageal variceal bleeding </strong>due to its<strong> longer activity and fewer side effects.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Desmopressin is not useful for treatment of nephrogenic diabetes insipidus:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> True. </strong>Desmopressin is<strong> ineffective </strong>in <strong>nephrogenic DI</strong> because the <strong>kidney does not respond to ADH.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Amiloride is used for treatment of lithium induced diabetes insipidus:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>True</strong>. Amiloride <strong>blocks </strong>the <strong>entry of lithium ions</strong> through <strong>sodium channels in the collecting duct cells</strong>, effectively <strong>mitigating the diabetes insip</strong>idus induced by<strong> lithium.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Desmopressin </strong>is effective for treating<strong> central diabetes insipidus </strong>because it <strong>acts on V2 receptors </strong>to <strong>mitigate the symptoms</strong>, but it <strong>does not </strong>work for<strong> nephrogenic diabetes insipidus</strong>, where the <strong>kidney is unresponsive to ADH</strong>.</span></span></span></p>",
    "correct_choice_id": 14570,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3951,
    "choices": [
      {
        "id": 15783,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ATP dependent Na channel blocker</span></span></span></p>"
      },
      {
        "id": 15784,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ATP dependent K channel blocker</span></span></span></p>"
      },
      {
        "id": 15785,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ATP dependent Cl channel blocker</span></span></span></p>"
      },
      {
        "id": 15786,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ATP dependent Ca channel blocker</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism action of sulfonylureas is?</span></span></span></p>",
    "unique_key": "Q2332654",
    "question_audio": null,
    "question_video": null,
    "map_id": 36154,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. ATP dependent K channel blocker</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sulfonylureas</strong> bind to <strong>SFU receptors in beta cells of pancreas.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These <strong>inhibit ATP dependent K channels (KATP).</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of K channels<strong> stop the efflux of K from beta cells</strong> leading to slight <strong>depolarization.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This <strong>opens calcium channels </strong>leading to<strong> complete depolarization and release of insulin.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. ATP dependent Na channel blocker:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect. Sulfonylureas do not interact</strong> with <strong>sodium channels</strong> in their primary mechanism of action.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. ATP dependent Cl channel blocker:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect. Chloride channels </strong>are <strong>not</strong> involved in the mechanism of action of <strong>sulfonylureas.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. ATP dependent Ca channel blocker:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong>. While <strong>calcium channels </strong>play a role in the mechanism, <strong>sulfonylureas do not</strong> <strong>block</strong> them; instead, they cause them to <strong>open by depolarizing the cell membrane</strong> through the<strong> inhibition of potassium efflux.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture13.jpg\" style=\"height:535px; width:1000px\" /><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture14.jpg\" style=\"height:538px; width:1000px\" /></span></u></strong></span></span></p>",
    "correct_choice_id": 15784,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  }
];
        let quizName = 'Endocrine System';
        let hierarchy = ["Cerebellum", "qBank", "Pharmacology"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        const urlParams = new URLSearchParams(window.location.search);
        currentQuestionIndex = Math.min(parseInt(urlParams.get('startAt')) || 0, questionsData.length - 1);

        function goBack() {
            if (isQuizCompleted || confirm('Are you sure you want to leave the quiz? Your progress will be lost.')) {
                window.history.back();
            }
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                setTimeout(processAnswer, 300);
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            setTimeout(showSolution, 1500);
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }
            
            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (!window.location.pathname.endsWith('custom_quiz.html')) {
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>